

Defining blood-induced microglia functions in neurodegeneration through multiomic profiling

Received: 4 November 2021

Accepted: 24 April 2023

Published online: 8 June 2023

 Check for updates

Andrew S. Mendiola ^{1,2}, Zhaoqi Yan ^{1,2}, Karuna Dixit ^{1,2}, Jeffrey R. Johnson¹, Mehdi Bouhaddou^{3,4}, Anke Meyer-Franke¹, Min-Gyoung Shin¹, Yu Yong^{1,2}, Ayushi Agrawal ¹, Eilidh MacDonald ^{1,2}, Gayathri Muthukumar¹, Clairice Pearce^{1,2}, Nikhita Arun^{1,2}, Belinda Cabriga^{1,2}, Rosa Meza-Acevedo^{1,2}, Maria del Pilar S. Alzamora ^{1,2}, Scott S. Zamvil ⁵, Alexander R. Pico ¹, Jae Kyu Ryu ^{1,2,5}, Nevan J. Krogan ^{1,4,6} & Katerina Akassoglou ^{1,2,5} 

Blood protein extravasation through a disrupted blood–brain barrier and innate immune activation are hallmarks of neurological diseases and emerging therapeutic targets. However, how blood proteins polarize innate immune cells remains largely unknown. Here, we established an unbiased blood-innate immunity multiomic and genetic loss-of-function pipeline to define the transcriptome and global phosphoproteome of blood-induced innate immune polarization and its role in microglia neurotoxicity. Blood induced widespread microglial transcriptional changes, including changes involving oxidative stress and neurodegenerative genes. Comparative functional multiomics showed that blood proteins induce distinct receptor-mediated transcriptional programs in microglia and macrophages, such as redox, type I interferon and lymphocyte recruitment. Deletion of the blood coagulation factor fibrinogen largely reversed blood-induced microglia neurodegenerative signatures. Genetic elimination of the fibrinogen-binding motif to CD11b in Alzheimer’s disease mice reduced microglial lipid metabolism and neurodegenerative signatures that were shared with autoimmune-driven neuroinflammation in multiple sclerosis mice. Our data provide an interactive resource for investigation of the immunology of blood proteins that could support therapeutic targeting of microglia activation by immune and vascular signals.

Vascular and immune signals are potent activators of the innate immune response in a wide range of autoimmune, inflammatory and infectious diseases in the brain and the periphery^{1–4}. Innate immune cells integrate environmental signals to rapidly activate target genes and

perform specialized cellular functions⁵. Pathogenic activation of microglia contributes to oxidative stress, inflammation and neurodegeneration in both Alzheimer’s disease (AD) and multiple sclerosis (MS)⁶. Blood–brain barrier (BBB) disruption is an early pathological feature

¹Gladstone Institutes, San Francisco, CA, USA. ²Center for Neurovascular Brain Immunology at Gladstone and UCSF, San Francisco, CA, USA.

³Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA, USA. ⁴Quantitative Biosciences Institute, University of California, San Francisco, CA, USA. ⁵Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. ⁶Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA. ✉e-mail: kakassoglou@gladstone.ucsf.edu

linked to microglial activation, neurodegeneration and progression in MS, AD and other neurological diseases^{3,7}. Upon BBB disruption, toxic blood proteins extravasate into the brain, altering the environmental milieu⁷⁻¹⁰. Blood coagulation and complement pathways are key activators of innate immunity that are coregulated in aging, cancer, and neurological, psychiatric and infectious diseases¹¹⁻¹⁷. The blood coagulation protein fibrinogen is converted to insoluble fibrin at sites of vascular damage and induces microglia activation and neurodegeneration via the CD11b-CD18 integrin receptor (also known as complement receptor 3 (CR3), $\alpha_M\beta_2$ or Mac-1)^{3,18-21}. CR3 also binds additional structurally unrelated ligands with diverse immunomodulatory functions, including complement protein iC3b, which regulates synaptic, pathogen and debris clearance via phagocytosis^{1,22}. However, how microglia integrate extracellular signals at sites of cerebrovascular damage and the specificity of blood proteins controlling innate immune cell polarization in disease remain poorly understood.

We report a blood-induced microglia gene network and show that blood proteins elicit distinct receptor-mediated transcriptional changes and signaling programs in innate immune cells. We provide a transcriptomic and phosphoproteomic atlas of fibrin-, iC3b- and lipopolysaccharide (LPS)-selective activation of innate immunity and reveal ligand-selective pathways with differential functions in MS and AD mice. We identify fibrin-CD11b signaling as causal for neurotoxic microglial programming in disease. Moreover, our study provides a resource for the investigation of the immunology of blood proteins in inflammatory, autoimmune and neurodegenerative diseases.

Results

Blood-induced microglial transcriptomic profiling

To discover the molecular programs controlling microglial and macrophage polarization by blood proteins, we developed an unbiased blood-innate immunity multiomic and genetic loss-of-function pipeline consisting of deep sequencing of blood-induced transcriptomes, functional single-cell and oxidative stress transcriptomics, global phosphoproteomics and integration with innate immune signatures from AD and MS models (Extended Data Fig. 1). To determine the blood-induced transcriptome in microglia, we stereotactically delivered wild-type (WT) plasma to the brain, followed by RNA sequencing (RNA-seq) analysis of sorted microglial cells (Fig. 1a and Supplementary Table 1). By unbiased analyses of differentially expressed genes (DEGs), gene ontology (GO) networks and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, we showed that WT plasma induced widespread microglial transcriptional changes, including changes involving genes related to oxidative stress (for example, *Hmox1*, *Romo1*, *Gpx1*), disease-associated microglia (DAM) (for example, *Cst7*, *Spp1*) and the cell cycle (for example, *Top2a*, *Cdkn2d*), as well as reactive oxygen species (ROS), oxidative phosphorylation, neurodegeneration, AD, glutathione metabolism and COVID-19 pathways (Fig. 1b-e and Supplementary Table 2). These changes were largely absent following stimulation with plasma derived from fibrinogen-deficient *Fga*^{-/-} mice but were relatively preserved following stimulation with complement 3-deficient (*C3*^{-/-}) or albumin-deficient (*Alb*^{-/-}) plasma

(Fig. 1b,c, Extended Data Fig. 2 and Supplementary Tables 2 and 3). Indeed, the number of genes in the blood-induced microglia gene network was reduced by 97%, with significant downregulation of 52% of the genes, when plasma was derived from *Fga*^{-/-} mice (Fig. 1f, Extended Data Fig. 3 and Supplementary Table 3), suggesting that fibrinogen is a key protein in the blood that induces microglia activation. Through unbiased KEGG pathway analysis of DEGs between *Fga*^{-/-} and WT plasma-stimulated microglia, we identified the 12 top pathways induced by fibrinogen, including ROS (for example, *Hmox1*, *Cox7a2*, *Slc25a5*), COVID-19 (for example, *Ccl12*, *Rps8*, *Rpl35*) and AD (for example, *Atp5e*, *Psm2*, *Tubb5*) (Fig. 1e,g). Similarly, microglia gene expression was reduced in response to plasma from *Fgg*^{y390-396A} mice, in which fibrinogen had been mutated to lack the CD11b-CD18 binding motif but retained normal clotting function^{19,23} compared with WT plasma (Fig. 1c and Supplementary Table 2). Whereas the effect of *C3*^{-/-} or *Alb*^{-/-} plasma on microglia was largely similar to that of WT plasma (five and three DEGs, respectively), *Fga*^{-/-} and *Fgg*^{y390-396A} plasma induced major gene expression changes in microglia (348 and 331 DEGs, respectively) (Fig. 1c, Extended Data Fig. 2 and Supplementary Table 2). These results are consistent with reduced demyelination in the corpus callosum induced by *Fga*^{-/-} or *Fgg*^{y390-396A} plasma compared with WT plasma or fibrinogen administration^{21,24}. Collectively, these results suggest that there is specificity among blood proteins in the induction of microglia transcriptional changes, indicating that fibrinogen signaling is a critical regulator in the blood for the induction of oxidative stress and disease-induced signatures in microglia following BBB leakage.

Single-cell RNA-seq reveals distinct fibrin and iC3b gene signatures


To determine how innate immune cells polarize in response to immune and vascular signals, we first generated single-cell RNA-seq (scRNA-seq) profiles from fibrin-, complement iC3b- or LPS-stimulated primary microglia (Fig. 2a-e and Extended Data Fig. 4). Gene set enrichment analysis (GSEA) of top DEGs identified fibrin-induced genes controlling oxidative stress and redox regulation (for example, *Cybb*, *Ncf1*, *Clec4e*) and the type 1 interferon (IFN)-stimulated gene (ISG) family (for example, *Isg15*, *Ifit3* and *Ifit2*), which were selectively enriched in cluster 4 'Mg-fibrin-cluster' (Fig. 2f). iC3b-treated cells overlapped with fibrin-treated cells (clusters 0, 1, 5 and 6; here termed 'fibrin-iC3b-clusters') and were characterized by 1,184 coregulated genes, with 111 genes (-9%) overlapping with LPS-induced gene response (Fig. 2c,d and Supplementary Table 4). Both fibrin and iC3b induced common gene signatures related to pathways of oxidative stress (for example, *Hmox1*, *Prdx6* and *Txnrd1*), phospholipid metabolism (for example, *Clqa*, *Sepp1* and *Clec7a*) and organization of extracellular matrix (ECM) (for example, *Ctsl*, *Lgals3* and *ApoE*) (Fig. 2f and Supplementary Table 4). As expected, LPS activated gene expression programs of the inflammatory response including mitogen-activated protein kinase (MAPK) activity in microglia (Fig. 2f and Supplementary Table 4). Overall, these results highlight ligand-selective gene circuits in microglia.

Fig. 1 | Transcriptional profiling of ligand-selective activation of blood-induced microglial responses in vivo. **a**, Schematic of experimental design for transcriptional profiling of blood-induced microglial responses. **b,c**, Volcano plots of DEGs from RNA-seq analysis of sorted microglia from plasma-injected brains. Comparisons between DEGs in microglia of brains injected with WT plasma versus aCSF or *Fga*^{-/-} plasma versus aCSF (**b**) and *Fga*^{-/-} plasma versus WT plasma, *Fgg*^{y390-396A} versus WT plasma or *Alb*^{-/-} versus WT plasma (**c**) are shown. The log₂ FC and -log₁₀ adjusted *P* value cutoffs were log₂ FC > 0.5, adjusted *P* < 0.1 with Wald test followed by Benjamini-Hochberg (BH) test correction. Top DEGs are shown. Data are from *n* = 6 *Fga*^{-/-}, *n* = 6 WT, *n* = 6 aCSF and *n* = 8 *Alb*^{-/-} mice. **d**, Coexpression GO networks upregulated in microglia by WT plasma. Adjusted *P* value < 0.1 by hypergeometric test and BH test correction.

e, GSEA plots of top upregulated and downregulated pathways in microglia from *Fga*^{-/-} plasma-injected versus WT plasma-injected brains. Adjusted *P* value < 0.1 by permutation test with BH test correction. **f**, Overlay of blood microglia GO network with microglial gene expression values from *Fga*^{-/-} plasma-injected mice. Red shading, genes upregulated in microglia by WT plasma; blue shading, genes downregulated in microglia by *Fga*^{-/-} plasma; orange border, **P* < 0.1 (Wald test followed by BH test correction). **g**, Coexpression KEGG pathway networks of top upregulated and downregulated pathways in microglia from *Fga*^{-/-} plasma-injected versus WT plasma-injected brains. Adjusted *P* < 0.1 by hypergeometric distribution and BH test correction. *P*_{adjust}, adjusted *P* value. Created with BioRender.com.

Next, we performed a similar analysis on mouse bone-marrow-derived macrophages (BMDMs), unstimulated or treated with either fibrin, complement iC3b or LPS. Like microglia, BMDMs largely clustered

into distinct ligand-induced transcriptional states, with clusters enriched for fibrin (clusters 1, 2, 5 and 6; termed ‘BMDM-fibrin-clusters’), iC3b (cluster 0; termed ‘BMDM-complement-cluster’) and LPS



(clusters 4 and 5; termed 'BMDM-LPS-clusters') (Fig. 3a–d, Extended Data Fig. 4f–i and Supplementary Table 5). Similar to stimulated microglia, GSEA identified fibrin-induced genes *Cxcl10*, *Hmox1*, *Ifit3*, *Prdx1*, *Clec4e*, *Nos2*, *Il1b* and *Stat1* linked with oxidative stress, IFN- γ response, lipid metabolism, and T and B cell recruitment (Fig. 3d,e and Extended Data Fig. 4j, Supplementary Table 5). By contrast, GO analysis of the BMDM-complement-cluster showed enrichment of pathways for host defense response, myeloid cell differentiation, innate immune and lymphocyte activation and of related genes (for example, *S100a8*, *S100a9*, *Cxcr4*, *Glul* and *Maf*) (Fig. 3d,e and Extended Data Fig. 4j). Antiviral gene signatures were identified as shared GO terms in both the fibrin and iC3b clusters (Fig. 3e and Extended Data Fig. 4l). As expected for LPS-primed macrophages⁵, LPS clusters were enriched in gene pathways for MAPK activity, inflammatory cytokine and chemokine production, and chemotaxis (for example, *Il1b*, *Il6* and *Tnf*) (Fig. 3d, Extended Data Fig. 4j and Supplementary Table 5). Pseudotime analysis showed a two-path transcriptional bifurcation from unstimulated to iC3b to the fibrin-induced state (path 1) or unstimulated to fibrin to the LPS-induced state (path 2) (Extended Data Fig. 5a,b and Supplementary Table 6), suggesting that the CR3 and TLR4 ligands induce distinct activation pathways. All cell clusters were enriched for monocyte-derived macrophage markers (for example, *Lyz2*, *Cd14* and *Ctsd*) and had low expression of monocyte-derived dendritic cell markers (for example, *Itgax*) (Extended Data Fig. 5c), suggesting that undifferentiated or contaminating cells were not a major driver of clustering. Together, these results show that fibrin polarization primarily promotes prooxidant, lipid metabolism and IFN- γ responses, whereas complement iC3b and LPS induce host defense and classical inflammatory states, respectively.

Phosphoproteomics reveal distinct fibrin and iC3b signaling

Although macrophage signal transduction pathways have been extensively studied for Toll-like receptor ligands²⁵, the downstream signaling cascades for CR3 ligand activation have not been characterized. We performed unbiased quantitative phosphoproteomics²⁶ using mass spectrometry to globally characterize the dynamics of protein phosphorylation in response to complement iC3b or fibrin stimulation in RAW 264.7 macrophages. Hierarchical clustering analysis of detected phosphorylation sites revealed distinct signaling profiles for fibrin and iC3b (Extended Data Fig. 6a,b and Supplementary Tables 7 and 8). Fibrin initially induced a greater increase in global phosphorylation relative to iC3b, as evidenced by a significant increase in the detection and abundance of differentially expressed phosphosites (DEPs) 1 h after treatment (Extended Data Fig. 6a–c and Supplementary Table 9). iC3b stimulation induced a greater number of detected phosphosites at 3 h after stimulation (Extended Data Fig. 6a–c and Supplementary Table 9), suggesting differential phosphorylation kinetics.

Next, we generated the fibrin and iC3b phosphoproteomic interaction networks. Fibrin and iC3b induced unique and dynamic phosphorylation events, with few DEPs shared among ligands (Fig. 4a,b and Supplementary Tables 8 and 9). Fibrin induced robust phosphorylation of proteins including integrin-associated focal adhesion adaptor protein paxillin (PXN), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit neutrophil cytosolic factor 2 (NCF2), and mitochondria oxidative phosphorylation and metabolic function voltage-dependent anion-selective channel protein 1 (VDAC1) (Fig. 4a and Supplementary Table 8). Fibrin induced phosphorylation of Cdc42/

Rac-activated serine/threonine protein kinase 2 (PAK2), which links Rho GTPases to cytoskeleton reorganization and nuclear signaling, and redox regulators SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 (SMARCA5) and elongation factor 1- δ (EEF1D) (Fig. 4a and Supplementary Table 8). Fibrin also induced phosphorylation of IFN regulatory factor 2 binding protein 2 (IRF2BP2), which is a transcriptional cofactor inducing VEGF expression and angiogenesis. iC3b induced phosphorylation of death domain-associated protein (DAXX), secreted phosphoprotein 1 (SPPI, also known as osteopontin), ETS variant transcription factor 6 (ETV6) and STIP1 homology and U-Box containing protein 1 (STUB1) (Fig. 4a and Supplementary Table 8). Fibrin and iC3b induced phosphorylation of MAP2K2 (also known as MEK2), NF- κ B-activating protein (NKAP) and Ran-binding protein 3 (RANBP3) (Fig. 4a and Supplementary Table 8). String functional enrichment identified differential pathways induced by fibrin including 'VEGF signaling', 'T cell receptor signaling', 'cytoskeleton organization' and 'focal adhesion' and by iC3b including 'regulation of RNA metabolic process', 'regulation of gene silencing' and 'cellular response to stress' (Fig. 4c and Supplementary Table 10). Phosphoproteomic GO pathway interaction networks showed that fibrin induced dynamic regulation of 'cytoskeleton organization' and 'positive regulation of catalytic activity' networks, whereas iC3b led to sustained activation of 'cellular response to stress' and 'negative regulation of transcription, DNA-templated' interaction networks (Extended Data Fig. 6d and Supplementary Table 10).

The regulation of phosphorylation signaling cascades is largely mediated by protein kinases. To predict kinase–substrate relationships, we bioinformatically calculated kinase activities from our phosphoproteomics data²⁶. We identified significant activation of MAPK1 (also known as extracellular signal-regulated kinase 2, ERK2) and serum-glucocorticoid kinase 1 (SGK1) at 1 h after fibrin but not iC3B treatment (Fig. 4d and Supplementary Table 11). At 3 h after stimulation, we observed significant activation of casein kinase II (CSNK2A1), S6 kinase (RPS5KA1), protein kinase C and D kinases, and pyruvate dehydrogenase kinases (PDK1–4) in iC3b-treated samples relative to fibrin-treated samples (Fig. 4d and Supplementary Table 11). Together, these results show that fibrin and iC3b induce differential phosphorylation events and kinase activities, suggesting that blood proteins induce distinct signal transduction pathways in innate immune cells.

Next, we validated the top proteins phosphorylated by fibrin in BMDMs, primary microglia and brain tissue from AD mice. Paxillin binds to the cytoplasmic domain of β 2 subunits of integrins including CD11b–CD18, and its phosphorylation initiates focal adhesion complex formation upon integrin engagement with ECM²⁷. Fibrin induced dynamic phosphorylation of paxillin at residue 83 (p-PXN) in BMDMs and primary microglia (Fig. 4e,f), consistent with fibrin activation of focal adhesions in platelets²⁸. MEK2 phosphorylates ERK1/2, resulting in increased cellular proliferation and migration, oxidative stress and inflammation. We tested the effects of fibrin on MEK2 phosphorylation and proinflammatory gene activation. Fibrin induced robust phosphorylation of MEK2 at residue 394 (p-MEK2) in BMDMs and microglia (Fig. 4e,g). Specific MEK2 inhibitor trametinib blocked p-MEK2 and reduced expression of fibrin-induced gene *Il1b* in fibrin-treated BMDMs (Extended Data Fig. 6e,f), suggesting that MEK2 activation mediates fibrin-induced proinflammatory gene expression. Similarly, treatment with the therapeutic monoclonal 5B8 antibody,


Fig. 2 | scRNA-seq analysis of ligand-selective activation of microglia.

a, UMAP plots of single microglial cells treated with fibrin, iC3b and LPS identified by unsupervised clustering analysis ($n = 16,196$ cells from two independent experiments). **b**, Fractions of cells in each Seurat cluster colored based on treatment label. **c**, UpSet plot showing a matrix layout of DEGs specific to a cluster (single filled circle with no vertical lines) and DEGs shared between clusters (filled circles connected with vertical lines). Vertical bar plot of the unique or overlapping DEGs in clusters (top). Horizontal bar plot of the

number of upregulated DEGs for a cluster (left). **d**, Heat map of top ten DEGs per single-cell cluster. Example GO molecular function terms and genes for a given cluster are shown. Five-hundred cells (maximum) were randomly selected from each cluster, as shown in **a**, for visualization. Gene expression is depicted as log-normalized scaled expression. **e**, List of selected top upregulated ligand-induced genes. **f**, GSEA plots of top GO terms for ligand-induced gene signatures. Adjusted $P < 0.05$ by Kolmogorov–Smirnov test with BH test correction. Exp., expression; unstim., unstimulated.

which targets the fibrin-binding site to the CD11b I-domain without affecting fibrin polymerization²⁹, blocked p-MEK2 in fibrin-treated BMDMs (Fig. 4h), suggesting that fibrin-induced phosphorylation is

receptor mediated. The cytosolic NADPH oxidase subunit NCF2 translocates to the plasma membrane upon phosphorylation by ERK1/2 and phosphatidylinositol-3-kinase, leading to NADPH oxidase activation






Fig. 3 | Single-cell RNA-seq analysis of ligand-selective activation of macrophages. a, UMAP plots of single BMDMs treated with fibrin, iC3b or LPS identified by unsupervised clustering analysis ($n = 17,625$ cells from six mice (fibrin), two mice (iC3b), four mice (LPS) and eight mice (unstimulated)). BMDMs are shown colored by treatment, Seurat cluster or both. **b**, Fraction of cells in each Seurat cluster colored based on treatment label. **c**, Heat map of top ten DEGs per single-cell cluster. Example GO molecular function terms and genes for a given cluster are shown. Five-hundred cells (maximum) were randomly selected

from each cluster, as shown in **a**, for visualization. Gene expression is depicted as log-normalized scaled expression. **d**, List of selected top upregulated ligand-induced genes. **e**, Coexpression GO term networks for iC3b (black-filled nodes), fibrin (red-filled nodes) and LPS (cyan-filled nodes) from scRNA-seq of BMDMs. Upregulated GO terms are shown as colored nodes, and gene coexpression overlap is shown as gray edges. $P < 0.10$ (fibrin and iC3b) and $P < 0.01$ (LPS) by GSEA Kolmogorov–Smirnov test without multiple test correction.

and ROS production³⁰. Fibrin induced phosphorylation of p-NCF2 in BMDMs and primary microglia (Fig. 4e,g), consistent with fibrin activation of NADPH oxidase and ROS generation^{20,29,31}. NADPH oxidase activation has been identified in progressive MS³² and has been implicated in neurodegeneration and cognitive impairment in AD mice^{10,20}. To test whether NCF2 was phosphorylated in disease models in vivo, we assessed NCF2 expression and activation in the brains of 5XFAD mice, a model of AD. p-NCF2 and total NCF2 were higher in 5XFAD than in non-transgenic (NTG) control mice at 12 months of age (Fig. 4i). Together, these results identify fibrin as a CD11b–CD18 ligand coupling integrin signaling with NADPH oxidase activation (Extended Data Fig. 7). They also reveal the phosphoproteome of fibrin and iC3b and demonstrate the specificity of blood proteins in controlling and integrating innate immune signaling pathways in disease.

Fibrin drives neurotoxic innate immune programs in MS mice

Oxidative injury is associated with neuronal loss and myelin damage and has been proposed as a key contributor to disease pathogenesis in MS and AD^{6,33,34}. As both transcriptomic and phosphoproteomic analyses identified oxidative stress as a key fibrin-induced pathway, we performed an unbiased overlay of the fibrin, iC3b and LPS gene signatures (this study) with oxidative stress central nervous system (CNS) innate immune signatures that have been defined in a model of MS³¹. Single-cell RNA-seq of oxidative stress producing cells (Tox-seq) in an experimental autoimmune encephalomyelitis (EAE) model previously identified distinct cell subsets polarized toward oxidative stress (MgV and Mpl clusters), whereas others were enriched in antigen-presenting and phagocytic genes (MgIII and MpIII clusters)³¹. We found that stimulation by fibrin or LPS but not iC3b recapitulated the core oxidative stress signature (for example, *Ncf2*, *Cybb*, *Sod2* and *Irg1*) expressed by ROS⁺ microglia and macrophages in EAE (Fig. 5a,b, Extended Data Fig. 8a and Supplementary Table 12). Fibrin-stimulated cells had the highest expression of prooxidant genes identified in oxidative stress-producing populations of microglia (MgV prooxidant signature *Clec4e*, *Saa3*, *Stat1* and *Ifitm3*) and infiltrating macrophages (Mpl prooxidant signature *Clec4e*, *Hmxo1*, *Cxcl10* and *Libt4*) from EAE (Fig. 5b and Supplementary Table 12). The microglial-shared iC3b–fibrin gene signature (for example, *C1qa*, *C1qa*, *Fcrls*, *Clec7a*, *Apoe*, *Sepp1*) was enriched in the EAE microglia antigen-presenting MgIII cluster³¹ (Fig. 5a,b and Supplementary Table 12). The BMDM iC3b gene signature was enriched in the EAE macrophage clusters MpV and MpVI (Fig. 5a,b), which were identified as phagocytic subsets based on their gene expression programs³¹. All treatments significantly downregulated the homeostatic microglia gene signature (for example, *Cx3cr1*, *Trem2*, *Bin1* and *Cst3*)^{31,35} (Fig. 5b and Extended Data Fig. 8b). The fibrin transcriptomic signature is consistent with reduced oxidative stress, demyelination, axonal damage and protection from paralysis in *Fgg*^{390–396A} mice and WT mice treated with fibrin-targeting antibody 5B8 in EAE^{19,24,29}. These data suggest that fibrin and complement iC3b are potent signals in neuroinflammatory lesions that recapitulate the polarization of function-specific innate immune responses, with

fibrin serving as a potent inducer of oxidative stress gene programs in microglia and peripheral macrophages.

Fibrin drives neurotoxic microglia programs in AD mice

We next used Tox-seq to analyze the transcriptomes of CD11b⁺ cells labeled for ROS production (as assessed by 2',7'-dichlorofluorescein diacetate (DCFDA)) via scRNA-seq from brains of NTG control or 5XFAD mice (Extended Data Fig. 8c–f). Using unbiased clustering analysis superimposed with functional ROS characterization, we identified four transcriptionally distinct CD11b⁺ clusters containing ROS⁺ and ROS[−] cell populations as visualized by UMAP (Fig. 6a,b and Supplementary Table 13). Most ROS⁺ microglia (50% of cells) from 5XFAD mice were found in microglia cluster 4 (cluster Mg4) (Fig. 6b), which had enrichment of genes involved in neurodegenerative microglial cell activation and iron transport (for example, *Apoe*, *Tyrobp* and *Fth1*) (Fig. 6c,d, Extended Data Fig. 8g,h and Supplementary Table 13). By contrast, genes known to negatively regulate ROS production, superoxide metabolism and maintenance of the microglial homeostatic signature were increased in ROS[−] microglia from 5XFAD mice (for example, *Nrros*, *Clk1* and *Zeb2*, respectively) (Fig. 6c,d). Differential gene expression analysis showed few changes in ROS⁺ compared with ROS[−] microglia from NTG mice (Extended Data Fig. 8i). Functional subcluster analysis of both 5XFAD microglia clusters revealed that subcluster 0 had the highest single-cell expression of ROS⁺ microglia (Fig. 6e, Tox-seq cluster overlay). Fibrin-induced genes were enriched in subcluster 0 (Fig. 6e, fibrin signature overlay). ROS⁺ microglia were significantly enriched for fibrin-induced and iC3b–fibrin-induced genes but not LPS-induced genes (Fig. 6f and Supplementary Table 12).


To test whether fibrin is necessary for microglial polarization toward neurotoxic phenotypes, we crossed 5XFAD to *Fgg*^{390–396A} mice and analyzed microglia by scRNA-seq. The 5XFAD:*Fgg*^{390–396A} mice have reduced neurodegeneration and are protected from cognitive impairment²⁰. We performed scRNA-seq of CD11b⁺ cells from 5XFAD:*Fgg*^{390–396A}, 5XFAD, *Fgg*^{390–396A} and NTG littermates (Fig. 7a,b and Extended Data Fig. 9a–d). Differential gene expression analysis of DAM clusters 1 and 2 identified 487 upregulated and 178 downregulated genes in microglia from 5XFAD:*Fgg*^{390–396A} compared with 5XFAD mice (Fig. 7c, Extended Data Fig. 9e and Supplementary Tables 14 and 15). In 5XFAD:*Fgg*^{390–396A} mice, microglia homeostatic genes were among the top upregulated genes (for example, *Cx3cr1*, *Siglech*, *Runx1*), whereas fibrin-induced genes (for example, *Fth1*, *Rnase4*, *Mif*) and known DAM markers (for example, *Cst7*, *Apoe*, *Tyrobp*) were among the top downregulated genes (Fig. 7c and Supplementary Table 15). The neurodegenerative microglia gene signature was significantly reduced in 5XFAD:*Fgg*^{390–396A} mice, whereas microglial homeostatic genes were expressed at control levels (Fig. 7d and Supplementary Table 15). The neurodegenerative signature downregulated in 5XFAD:*Fgg*^{390–396A} mice was related to TREM-2-associated genes³⁶ (*Tyrobp*, *CD68*, *Cst7*), iron-binding genes (*Fth1*, *Ftl1*) and lipid-binding genes (*Apoe*, *Fabp5*) (Fig. 7e). To validate these changes in situ, we performed immunohistochemistry in brains from 5XFAD and 5XFAD:*Fgg*^{390–396A} mice using the DAM and oxidative stress markers apolipoprotein E

Fig. 4 | Phosphoproteomics of fibrin and iC3b signaling in innate immune cells. **a**, Phosphoproteomic interaction networks for fibrin and iC3b. Selected phosphopeptides shown with phosphorylation as blue–red scheme and time points as rings. Adjusted $P < 0.05$. **b**, DEPs between fibrin and iC3b at each time point. **c**, Functional enrichment terms from fibrin or iC3b phosphorylation pathways. **d**, Kinase activities from the phosphoproteomic dataset. Differentially regulated kinases between fibrin and iC3b are indicated with black bounding. Kinases below the cutoff are in gray. **e**, Confocal microscopy and quantification of p-MEK2, p-PXN and p-NCF2 staining in BMDMs stimulated with fibrin or unstimulated (US). **f,g**, Immunoblot of p-PXN, PXN and GAPDH (**f**) and p-MEK2, MEK1/2, p-NCF2 and GAPDH (**g**) in primary rat microglia, US or stimulated with fibrin; FC compared with control is indicated. **h**, Microscopy and quantification of p-MEK2 staining in BMDMs left US or stimulated for 90 min with fibrin

alone or in the presence of 5B8 or IgG2b. **i**, Immunoblot of p-NCF2, NCF2 and GAPDH from 12-month-old 5XFAD or NTG mouse cortex. Signal ratios (delta) for p-NCF2–GAPDH and NCF2–GAPDH are shown. Data are from $n = 2$ (fibrin 1 h), $n = 2$ (iC3b 1 h), $n = 3$ (US 1 h), $n = 3$ (fibrin 3 h), $n = 3$ (iC3b 3 h) and $n = 3$ (US 3 h) independent experiments (**a–d**); $n = 3$ independent experiments in duplicate (**e**), representative of two independent experiments (**f,g**); $n = 4$ independent experiments in duplicates (**h**); or $n = 6$ (NTG) and $n = 5$ (5XFAD) mice (**i**). Statistics: two-sided Student's t test with BH test correction (**a** and **b**), FDR < 0.05 by hypergeometric test with BH correction (**c**), $P < 0.05$ by two-sided z test (**d**), two-tailed unpaired t test (**e**) or one-way ANOVA with Tukey's multiple comparisons test (**h**). Data are mean \pm s.e.m., and nuclei are labeled with DAPI (**e** and **h**). Scale bars, 10 μm (**e**); 50 μm (**h**). US, unstimulated.

(APOE) and GP91^{phox}, which Tox-seq had identified as highly enriched in ROS⁺ microglia. The frequency of double-positive APOE/GP91^{phox} cells surrounding amyloid plaques was reduced in 5XFAD:*Fgg*^{390-396A} compared with 5XFAD mice (Fig. 7f), suggesting that *ApoE* gene expression

and oxidative-stress-producing DAM around amyloid plaques are fibrin dependent. Overall, these results suggest that fibrin-CD11b signaling drives key microglia pathways including TyroBP, lipid metabolism and oxidative stress responses in neurodegeneration.






Fig. 5 | Unbiased overlay of ligand-selective gene signatures with innate immune cell subsets in EAE. a, UMAP of EAE microglia or macrophage Tox-seq clusters³¹ overlaid with primary microglia (top) or BMDM (bottom) ligand-activation signatures (this study). Expression is depicted as a log-normalized average modular score for each signature. CNS innate immune cell clusters are

numerically labeled and outlined to depict healthy and EAE samples (gray and orange, respectively). **b**, Dot plot of selected gene markers across the scRNA-seq datasets of primary microglia (left panel) and BMDMs (right panel) unstimulated or stimulated with fibrin or iC3b. Average gene expression is depicted as scaled log-normalized expression. Max., maximum; min., minimum.

Fibrin microglia signatures shared between AD and MS mice

We next compared the Tox-seq transcriptomic profiles of microglia between the 5XFAD and EAE models. The oxidative stress core signature identified in ROS⁺ microglia from EAE mice was also present in 5XFAD mice (Fig. 8a and Supplementary Table 16). Although 67 DEGs were shared between EAE and 5XFAD ROS⁺ microglia (for example, *Apoe*), the majority of genes were specific for either 5XFAD (132 DEGs) or EAE (170 DEGs), such as *Igf1* and *Il1b*, respectively (Fig. 8b,c). These results are in line with human microglial transcriptomics identifying partial overlap between MS and AD³⁷. Pathway analysis of the microglial oxidative stress genes shared among EAE and 5XFAD models identified enrichment in pathways related to blood coagulation and hemostasis (for example, *Plaur*, *Slc16a3*, *Eno1*), antigen presentation (for example, *H2-Ab1*, *H2-K1*, *Cd74*), neutrophil degranulation (for example, *B2m*, *Cstb*, *Bst2*) and the tyrosine kinase binding protein Tyrobp network (Fig. 8d, Extended Data Fig. 10a and Supplementary Table 16). We next overlaid the shared AD and EAE oxidative stress signature with the blood-induced microglia profiles (Fig. 8e). The WT plasma signature overlapped with the shared oxidative stress microglia signature, indicating that the dataset alignment identified blood-induced microglia genes both in MS and AD mice. *Fga*^{-/-} plasma largely reduced oxidative stress and disease-associated transcripts to control levels (Fig. 8e and Extended Data Fig. 10b,c), suggesting that fibrinogen is a key ligand in the blood that activates neurodegenerative

microglia responses. Taken together, these data suggest a pathogenic role for fibrin-induced microglia polarization in neurodegeneration in both MS and AD, demonstrating shared and unique drivers of innate immune-driven neurotoxicity.

Discussion

We report the first unbiased transcriptome and phosphoproteome of blood-induced polarization of innate immunity, revealing the selectivity and causal role of blood proteins in mediating neurotoxic microglial functions. Traditionally, blood leaks were considered to be secondary to inflammation, with largely interchangeable functions once they extravasated into the brain^{7,38}. Through in vivo genetic loss-of-function studies combined with unbiased comparative transcriptomics analysis, our study shows the specificity of blood proteins in differentially activating receptor-mediated immune responses required for pathogenic microglial gene programs in AD and MS models. Blood-induced prooxidant programming of neurotoxic microglia occurs along common molecular pathways across neurodegeneration and CNS autoimmunity. Fibrin-CD11b signaling was necessary for neurotoxic microglia programs in AD mice consisting of neurodegenerative, oxidative stress and lipid metabolism that were shared with an MS model. Given that immune, vascular and blood signals are key players in aging, neurological and peripheral diseases^{2,4,39}, our dataset represents a valuable resource for the study of novel pathways and





Fig. 6 | Single-cell oxidative stress transcriptome of microglia in 5XFAD mice. **a**, UMAP plot of single CD11b⁺ ROS⁻ and CD11b⁺ ROS⁺ cells identified by unsupervised clustering analysis ($n = 1,579$ cells from brains of three 5XFAD and three NTG mice) (left). UMAP of Tox-seq-labeled cells from 5XFAD or NTG mice. **b**, Fraction of cells in each Seurat cluster colored based on Tox-seq label. **c**, Volcano plot of enriched DEGs in CD11b⁺ ROS⁺ cells from 5XFAD mice. Dots depict average \log_2 FC and $-\log_{10}$ adjusted P values (\log_2 FC > 0.25, adjusted $P < 0.05$ with MAST statistical test with BH correction). **d**, Dot plot of selected gene markers from **c**. Average gene expression and cell population expression is depicted as log-normalized scaled expression and percentage, respectively.

e, UMAP plots of functional subcluster analysis of 5XFAD CD11b⁺ ROS⁺ and CD11b⁺ ROS⁻ microglia overlaid with Tox-seq label (left) or in vitro fibrin signature (right). **f**, Violin plots of fibrin, iC3b-fibrin and LPS gene signature overlays with Tox-seq-labeled microglia. Violin plots depict minimum, maximum and median expression, with points showing single-cell expression levels. Box plots show the first to third quartiles (25–75% box bounds) with median values indicated and upper and lower whiskers extending to 1.5 \times interquartile range. $n = 1,579$ cells from brains of three 5XFAD and three NTG mice. $P < 0.05$ as determined by two-way ANOVA with Tukey's multiple comparison test.

biomarkers and for discovery of drugs that selectively target pathogenic innate immunity in aging and inflammatory, autoimmune and neurodegenerative diseases.


Our study provides a mechanistic link between cerebral vascular pathology and neurodegeneration by identifying fibrin-CD11b signaling as an apical inducer of neurotoxic pathways in innate immune cells.



Our model proposes that fibrin binding to CD11b–CD18 induces an outside-in integrin signaling cascade to initiate focal adhesion complex formation, activate MAPK and transactivate NADPH oxidase to induce proinflammatory, oxidative stress and IFN- γ signaling responses. Fibrin also induces phosphorylation of SMARCA5, RANBP3 and NUP98, suggesting regulation of nuclear import, chromatin remodeling and transcription⁴⁰. Formation of multiprotein adhesion complexes that link the ECM to the cytoskeleton, MAPK signaling, oxidative stress and gene expression identify fibrin as a mechanoregulator of CD11b–CD18 integrin effector functions in innate immune cells^{27,41,42}. Indeed, increased fibrin deposition, paxillin, MAPK and sustained MEK2 activation, and NADPH oxidase activity promote oxidative injury and mediate neurodegeneration and synaptic dysfunction in both MS and AD^{6,20,43–47}. In addition to NADPH oxidase, we identified mitochondrial VDAC1 and *ApoE* as induced by fibrin, suggesting that fibrin-induced oxidative stress may be mediated by multiple pathways. We also identified fibrin as a potent activator of STATs, ISGs and IFN- γ response, which induces

neuronal dysfunction in AD⁴⁸ and T cell effector functions in MS and autoimmune diseases⁴⁹. Fibrin could thus be a driver of IFN- γ response in disease. Together, these results identify fibrin as a key signal required for pathogenic polarization of immune cells at sites of vascular damage.

We discovered unique and shared transcriptomic and phosphoproteomic signatures induced by fibrin and iC3b, indicating that ligand-biased CR3 signaling may underlie the pleiotropic functions of CR3 in innate immune cell polarization^{50–52}. Our results suggest that limiting fibrin-induced innate immune responses may suppress oxidative injury and neurodegeneration, whereas suppressing complement may preferentially reduce phagocytosis and antiviral immune responses. iC3b-specific signatures could also be relevant to complement diseases such as C3 glomerulopathy¹. Ligation of CR3 by fibrin and iC3b may lead to differential conformational changes in its ectodomain, leading to ligand-biased outside-in signaling⁴¹. The stoichiometry and spatial distribution of fibrin and iC3b may also contribute to biased ligand signaling and transactivation of other receptors. Fibrin deposits and



complement activation may affect immunopathogenesis of intracerebral hematoma in conditions such as stroke and traumatic brain injury, in addition to neurodegenerative diseases³³. Future studies will

be necessary to determine how the cross-talk of the fibrinogen and complement pathways orchestrate oxidative injury and phagocytic signaling cascades, respectively. As CR3 mediates both protective

Fig. 8 | Comparison of microglial oxidative stress signature induced by neurodegeneration and autoimmunity. **a**, UMAP plot of 5XFAD Tox-seq clusters overlaid with EAE microglial oxidative stress genes signature (left). Violin plots of EAE oxidative stress signature enrichment in 5XFAD and NTG mice (right); $n = 1,579$ cells from brains of three 5XFAD and three NTG mice. Violin plots depict minimum, maximum and median expression, with points showing single-cell expression levels. Box plots show the first to third quartiles (25–75% box bounds) with median values indicated and upper and lower whiskers extending to 1.5 \times interquartile range. **b**, Venn diagram of oxidative stress genes

in CD11b⁺ ROS⁺ microglia from 5XFAD or EAE. **c**, UMAP plots of shared and unique oxidative stress microglia genes in 5XFAD and EAE. Gene expression overlays for *ApoE*, *Igf1* and *Illb* are shown. Gene expression is depicted as log-normalized scaled expression. The red outline demarcates microglial cells in a ROS-enriched cluster. Representative genes shared between or specific to 5XFAD and EAE Tox-seq are shown. **d**, Metascape analysis of top significant gene pathways shared in ROS⁺ microglia from 5XFAD and EAE mice. **e**, Dot plot of gene expression from blood microglia profiles overlaid with the 5XFAD and EAE shared oxidative stress gene signature in microglia as shown in **b**.

and damaging immune functions, strategies to target ligand-selective activation pathways may have therapeutic benefits⁸. Fibrin–CD11b signaling is required for pathogenic innate immune activation in the brain and periphery^{19,20,23,29,54–56}. *Fgg*^{390–396A} mice and those treated with the fibrin-targeting 5B8 antibody show protection against neurodegeneration and cognitive impairment in AD models and against paralysis and axonal damage in EAE^{19–21,24}. Protection from neurodegeneration upon inhibition of fibrin–CD11b signaling may be due to selective suppression of neurotoxic pathways in microglia, such as ApoE, IFN-I and oxidative stress pathways identified in this study^{32,34,49,57}. Thus, fibrin-targeting immunotherapy could be a therapeutic strategy in AD and MS without adverse anticoagulant effects or global suppression of innate immunity.

The resource we provide here should be considered with some caveats. As in vitro microglia cultures do not fully recapitulate in vivo homeostatic signatures⁵⁸, we also validated the ligand-selective signatures in vivo. Antibody-depleted plasma for fibrin, C3 or other blood proteins could complement the genetic depletion used in this study. Our phosphoproteomic analysis was performed in RAW 264.7 cells owing to their transcriptomic similarity to BMDMs, their use in phosphoproteomic studies^{25,59} and because of the technical demand for high cell numbers. We validated fibrin-induced phosphosites identified in RAW 264.7 cells in BMDMs and primary microglia and in 5XFAD mice, suggesting that the phosphorylation events also occur in vivo. Future studies in primary cells with additional concentrations and time points could be used to assess differential signaling pathways. For our comparative transcriptomic analysis, we selected three ligands—fibrin, iC3b and LPS—in macrophages and microglia owing to their broad and diverse immune roles in vascular, inflammatory and infectious disease. We selected fibrin and iC3b to study ligand-biased signaling of CD11b–CD18. Future studies could use our platform to compare additional complement and coagulation activators in other cell types. Another potential limitation was that protein aggregates could induce signaling independent of specific ligand-receptor interactions. However, we found specific receptor-mediated transcriptomic programs for blood proteins in vivo and suppression of the neurodegenerative gene signature in 5XFAD:*Fgg*^{390–396A} mice, indicating the distinct transcriptional programs of blood proteins are not due to aggregate protein formation. Although the results of transcriptomic analysis in 5XFAD:*Fgg*^{390–396A} mice support the fibrin-induced microglia response being CD11b dependent, they do not exclude direct or indirect effects of fibrin on other cellular targets in the brain³. The Trem2 pathway was induced in microglia in 5XFAD mice but not in the healthy brain by the blood, potentially owing to the difference in pathology as well as the age of the mice and the time points in the study. We performed Tox-seq analysis in 5XFAD mice, an AD model dependent on immune and vascular mechanisms^{20,60}. Future studies could use Tox-seq to characterize neurotoxic innate immune responses in other neurodegeneration models with different etiologies to discover additional pathways related to disease progression.

In summary, we demonstrated that blood-induced polarization of innate immunity is causal for the induction of neurotoxic microglial programming in disease. By establishing a blood-innate immunity multiomic and genetic loss-of-function pipeline, we defined fibrin as

a unique blood protein required for microglial polarization to oxidative stress and neurodegenerative phenotypes in MS and AD mice. Our study uncovers principles of distinct transcriptomic and phosphoproteomic events induced by immune and vascular signals and their contributions to immune diversity in autoimmunity and neurodegenerative disease. Furthermore, we lay the groundwork for future experiments to define the spatiotemporal regulation of blood-induced innate immune cell polarization, which may enable discovery of selective therapeutic strategies in inflammatory, neurological and infectious diseases.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41590-023-01522-0>.

References

- Hajishengallis, G., Reis, E. S., Mastellos, D. C., Ricklin, D. & Lambris, J. D. Novel mechanisms and functions of complement. *Nat. Immunol.* **18**, 1288–1298 (2017).
- Labzin, L. I., Heneka, M. T. & Latz, E. Innate immunity and neurodegeneration. *Annu. Rev. Med.* **69**, 437–449 (2018).
- Petersen, M. A., Ryu, J. K. & Akassoglou, K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. *Nat. Rev. Neurosci.* **19**, 283–301 (2018).
- Medzhitov, R. The spectrum of inflammatory responses. *Science* **374**, 1070–1075 (2021).
- Glass, C. K. & Natoli, G. Molecular control of activation and priming in macrophages. *Nat. Immunol.* **17**, 26–33 (2016).
- Lassmann, H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease. *J. Neural Transm.* **118**, 747–752 (2011).
- Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat. Rev. Neurol.* **14**, 133–150 (2018).
- Akassoglou, K. The immunology of blood: connecting the dots at the neurovascular interface. *Nat. Immunol.* **21**, 710–712 (2020).
- Strickland, S. Blood will out: vascular contributions to Alzheimer’s disease. *J. Clin. Invest.* **128**, 556–563 (2018).
- Iadecola, C. The pathobiology of vascular dementia. *Neuron* **80**, 844–866 (2013).
- Heurich, M., Focking, M., Mongan, D., Cagney, G. & Cotter, D. R. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. *Mol. Psychiatry* **27**, 127–140 (2021).
- Chan, J. P. et al. Blood coagulation factor fibrinogen in tumor pathogenesis of central nervous system B-cell lymphoma. *Am. J. Pathol.* **191**, 575–583 (2021).
- Magliozzi, R. et al. Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis. *Ann. Clin. Transl. Neurol.* **6**, 2150–2163 (2019).

14. Jaeger, P. A. et al. Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. *Mol. Neurodegener.* **11**, 31 (2016).
15. Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. *Nat. Med.* **26**, 1609–1615 (2020).
16. Markiewski, M. M., Nilsson, B., Ekdahl, K. N., Mollnes, T. E. & Lambris, J. D. Complement and coagulation: strangers or partners in crime? *Trends Immunol.* **28**, 184–192 (2007).
17. Bekassy, Z., Lopatko Fagerstrom, I., Bader, M. & Karpman, D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. *Nat. Rev. Immunol.* **22**, 411–428 (2022).
18. Davalos, D. & Akassoglou, K. Fibrinogen as a key regulator of inflammation in disease. *Semin. Immunopathol.* **34**, 43–62 (2012).
19. Adams, R. A. et al. The fibrin-derived $\gamma^{377-395}$ peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. *J. Exp. Med.* **204**, 571–582 (2007).
20. Merlini, M. et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer's disease model. *Neuron* **101**, 1099–1108.e1096 (2019).
21. Ryu, J. K. et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. *Nat. Commun.* **6**, 8164 (2015).
22. Hammond, T. R., Marsh, S. E. & Stevens, B. Immune signaling in neurodegeneration. *Immunity* **50**, 955–974 (2019).
23. Flick, M. J. et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin $\alpha_M\beta_2$ binding motif. *J. Clin. Invest.* **117**, 3224–3235 (2007).
24. Davalos, D. et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. *Nat. Commun.* **3**, 1227 (2012).
25. Weintz, G. et al. The phosphoproteome of Toll-like receptor-activated macrophages. *Mol. Syst. Biol.* **6**, 371 (2010).
26. Bouhaddou, M. et al. The global phosphorylation landscape of SARS-CoV-2 infection. *Cell* **182**, e619 (2020).
27. Sutherland, T. E., Dyer, D. P. & Allen, J. E. The extracellular matrix and the immune system: a mutually dependent relationship. *Science* **379**, eabp8964 (2023).
28. Guidetti, G. F., Torti, M. & Canobbio, I. Focal adhesion kinases in platelet function and thrombosis. *Arterioscler. Thromb. Vasc. Biol.* **39**, 857–868 (2019).
29. Ryu, J. K. et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. *Nat. Immunol.* **19**, 1212–1223 (2018).
30. Panday, A., Sahoo, M. K., Osorio, D. & Batra, S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. *Cell Mol. Immunol.* **12**, 5–23 (2015).
31. Mendiola, A. S. et al. Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. *Nat. Immunol.* **21**, 513–524 (2020).
32. Fischer, M. T. et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. *Brain* **135**, 886–899 (2012).
33. Dong, Y. et al. Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. *Nat. Neurosci.* **24**, 489–503 (2021).
34. Venkataraman, A. V. et al. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease. *Sci. Transl. Med.* **14**, eabk1051 (2022).
35. Butovsky, O. & Weiner, H. L. Microglial signatures and their role in health and disease. *Nat. Rev. Neurosci.* **19**, 622–635 (2018).
36. Colonna, M. The biology of TREM receptors. *Nat. Rev. Immunol.* <https://doi.org/10.1038/s41577-023-00837-1> (2023).
37. Absinta, M. et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. *Nature* **597**, 709–714 (2021).
38. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat. Rev. Immunol.* **20**, 355–362 (2020).
39. Yang, A. C. et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis. *Nature* **583**, 425–430 (2020).
40. Franks, T. M. & Hetzer, M. W. The role of Nup98 in transcription regulation in healthy and diseased cells. *Trends Cell Biol.* **23**, 112–117 (2013).
41. Kanchanawong, P. & Calderwood, D. A. Organization, dynamics and mechanoregulation of integrin-mediated cell-ECM adhesions. *Nat. Rev. Mol. Cell Biol.* **24**, 142–161 (2023).
42. Baeten, K. M. & Akassoglou, K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. *Dev. Neurobiol.* **71**, 1018–1039 (2011).
43. Malkov, A. et al. $A\beta$ initiates brain hypometabolism, network dysfunction and behavioral abnormalities via NOX2-induced oxidative stress in mice. *Commun. Biol.* **4**, 1054 (2021).
44. Park, L. et al. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. *Proc. Natl Acad. Sci. USA* **105**, 1347–1352 (2008).
45. Chun, Y. S. et al. MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's Disease. *Mol. Psychiatry* **27**, 4770–4780 (2022).
46. Ten Bosch, G. J. A., Bolk, J., t Hart, B. A. & Laman, J. D. Multiple sclerosis is linked to MAPK(ERK) overactivity in microglia. *J. Mol. Med.* **99**, 1033–1042 (2021).
47. Caltagarone, J. et al. Paxillin and hydrogen peroxide-inducible clone 5 expression and distribution in control and Alzheimer disease hippocampi. *J. Neuropathol. Exp. Neurol.* **69**, 356–371 (2010).
48. Roy, E. R. et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. *J. Clin. Invest.* **130**, 1912–1930 (2020).
49. Gonzalez-Navajas, J. M., Lee, J., David, M. & Raz, E. Immunomodulatory functions of type I interferons. *Nat. Rev. Immunol.* **12**, 125–135 (2012).
50. Cao, C. et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. *J. Clin. Invest.* **120**, 1971–1980 (2010).
51. Czirr, E. et al. Microglial complement receptor 3 regulates brain $A\beta$ levels through secreted proteolytic activity. *J. Exp. Med.* **214**, 1081–1092 (2017).
52. Lamers, C., Pluss, C. J. & Ricklin, D. The promiscuous profile of complement receptor 3 in ligand binding, immune modulation, and pathophysiology. *Front. Immunol.* **12**, 662164 (2021).
53. Zille, M. et al. Novel targets, treatments, and advanced models for intracerebral haemorrhage. *eBioMedicine* **76**, 103880 (2022).
54. Silva, L. M. et al. Fibrin is a critical regulator of neutrophil effector function at the oral mucosal barrier. *Science* **374**, eabl5450 (2021).
55. Steinbrecher, K. A. et al. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin $\alpha_M\beta_2$ engagement of fibrinogen. *Cancer Res.* **70**, 2634–2643 (2010).
56. Vidal, B. et al. Amelioration of Duchenne muscular dystrophy in mdx mice by elimination of matrix-associated fibrin-driven inflammation coupled to the $\alpha_M\beta_2$ leukocyte integrin receptor. *Hum. Mol. Genet.* **21**, 1989–2004 (2012).
57. Montagne, A. et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. *Nature* **581**, 71–76 (2020).

58. Gosselin, D. et al. An environment-dependent transcriptional network specifies human microglia identity. *Science* **356**, eaal3222 (2017).
59. Hargreaves, D. C., Horng, T. & Medzhitov, R. Control of inducible gene expression by signal-dependent transcriptional elongation. *Cell* **138**, 129–145 (2009).
60. Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. *Cell* **170**, 649–663.e613 (2017).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Methods

Animals

C57BL/6J and B6.SJL-Tg (APPSwF1lon,PSENI*M146L*L286V) 6799Vas/Mmjax (5XFAD) mice (034840-JAX) were purchased from the Jackson Laboratory (JAX) and backcrossed in a C57BL/6J background for more than 30 generations⁶¹. *Fga*^{-/-} and *Fgg*^{y390-396A} mice^{62,63} were obtained from J. Degen (University of Cincinnati, OH, USA). 5XFAD mice were crossed with *Fgg*^{y390-396A} mice to generate 5XFAD:*Fgg*^{y390-396A} mice. Male and female mice were used in this study. Sprague–Dawley female rats with litters were purchased from Charles River. Animals were housed under Institutional Animal Care and Use Committee guidelines in a temperature and humidity-controlled facility with a 12 h light–12 h dark cycle and ad libitum feeding. Animal protocols were approved by the Committee of Animal Research at the University of California San Francisco and in accordance with the National Institutes of Health guidelines.

Plasma injection for microglia RNA-seq

Citrate plasma from 8–11-week-old *C3*^{-/-} female (029661, JAX)⁶⁴ and *Alb*^{-/-} female (025200, JAX)⁶⁵ mice was obtained from JAX. Citrate plasma was isolated from WT C57BL/6J, *Fga*^{-/-} and *Fgg*^{y390-396A} mice as previously described²¹. Plasma or artificial cerebrospinal fluid (aCSF) control was bilaterally injected (1.5 μ l, 0.3 μ l min⁻¹) into the corpus callosum of male C57BL/6J mice, as previously described²¹. Twenty-four hours later, two mice were pooled per replicate, and microglia were isolated from 1-mm tissue blocks spanning the injection sites. Tissues were incubated in lysis buffer (1 mg ml⁻¹ collagenase D (Sigma-Aldrich), 0.05 mg ml⁻¹ DNaseI (Sigma-Aldrich), 3 μ M actinomycin D (ActD) diluted in Dulbecco's phosphate-buffered saline (DPBS) with Ca²⁺ Mg²⁺ (Thermo Fisher Scientific) for 30 min at 37 °C. Myelin was depleted using a debris removal kit (Miltenyi Biotec) as previously described⁶⁶. Cells were treated with Fc-block in fluorescence-activated cell sorting (FACS) buffer (DPBS supplemented with 0.2% bovine serum albumin, Thermo Fisher Scientific) for 5 min at 4 °C then incubated with primary antibodies for 30 min at 4 °C. The following primary antibodies from BioLegend were used at 1:200 dilution: CD11b (M1/70) and CD45 (30-F11). Then, 15,000 to 20,000 CD45^{lo} CD11b⁺ microglia were FACS sorted into tubes containing RLT plus lysis buffer (Qiagen) supplemented with 1% 2-mercaptoethanol and 0.25% reagent DX (Qiagen) using a FACS Aria II with BD FACSDiva v.8 and FlowJo v.10 software for analyses. Cells were gated on side scatter area (SSC-A) and forward scatter area (FSC-A) size, and then doublet discrimination was performed with FSC-H and FSC-W (height and width) parameters. Microglia lysates were frozen and stored at -80 °C until they were processed for RNA-seq.

Bulk RNA-seq of microglia

Samples from the plasma injection experiment were processed for RNA-seq using an Ovation RNA-seq System V2 low input kit (NuGEN) as previously described³¹. Libraries were equimolar pooled and sequenced on a NovaSeq 6000 S4 (Illumina) with 200 paired-end reads to a depth of >50 million reads per library. Paired-end fastq files were processed using the Nextflow RNA-seq pipeline⁶⁷ with next flow v.20.12.0-edge in Singularity with default nf-core/rnaseq v.3.0 parameters and packages. Fastq files were mapped to the GRCh38/mm10 genome (downloaded from nf-core). Gene analyses were performed in R v.4.2.0 using DeSeq2 v.1.36.0 on the salmon.merged.gene_counts_scaled file. Reads with fewer than three counts per gene across replicates were filtered. Three samples did not pass RNA and cDNA library quality control (QC) testing; another was removed owing to large deviation on principal component analysis (PCA) and poor sequence alignment. No other samples or animals were excluded from analyses. For differential gene analysis, the *results* function in DeSeq2 was used with contrast to test between two genotypes and treatments of interest. Significance was determined by abs(log₂

fold change (FC)) > 0.5 and adjusted *P* < 0.1 unless otherwise stated. Unbiased KEGG analysis was performed using clusterProfiler with default parameters and pvalueCutoff set to 0.1. The blood microglia gene network was generated in Cytoscape v.3.7.2 (ref. 68) using upregulated DEGs identified in WT plasma compared with aCSF samples (Supplementary Table 3). GO pathways were determined using functional enrichment analysis in String⁶⁹ with default parameters visualized in Cytoscape.

Cell culture

Primary microglia were prepared from neonatal rats at postnatal day 5 or from C57BL/6J mice at postnatal days 2–3 as previously described^{21,31}. Viability was assessed using trypan blue. Microglia cultures from one litter were used for each independent experiment. BMDMs were prepared from male and female 12–20-week-old mice as previously described^{21,31} and used for experiments after 6 or 7 days of differentiation. For BMDM scRNA-seq, two male or two female mice were pooled per experiment. Individual animals were used for biological replicates unless otherwise stated. RAW 264.7 macrophages were obtained from ATCC and cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS).

scRNA-seq of ligand stimulated cells

Fibrin-coated 24-well culture plates (Corning) were prepared as previously described²⁹. Then, 10 μ g ml⁻¹ iC3b (CompTech; A115) in HEPES pH 7.2 buffer was immobilized on culture plates by 1 h incubation at 37 °C followed by overnight incubation in a 37 °C humidified chamber. For fibrin or iC3b stimulation, BMDMs or primary microglia were seeded into fibrin-coated or iC3b-coated wells at 5.0 \times 10⁵ cells ml⁻¹. Control wells were treated with the same buffer void of fibrin or iC3b. For LPS stimulation, BMDMs or microglia were seeded into 24-well tissue-culture-treated plates at 5.0 \times 10⁵ cells ml⁻¹, allowed to adhere overnight, then treated with 100 ng ml⁻¹ LPS (Sigma-Aldrich, O55:B5) for the durations indicated in figure legends. Following stimulation, adherent cells were lifted with accutase (StemCell Technologies) and viable cells were counted by trypan blue, then resuspended in RPMI with 5% FBS and used for scRNA-seq.

For scRNA-seq library preparation, BMDMs or primary microglia were processed with a Chromium Single Cell 3' v.2 kit according to the manufacturer's guidelines (10x Genomics). Libraries were balanced to achieve a minimum of 75,000 reads per cell and run on two lanes of a NovaSeq 6000 (Illumina) with 150 paired-end reads. Samples were demultiplexed, and fastq files were used to align reads to the mm10 reference assembly (downloaded 2019) and aggregated using the Cell Ranger count and aggr packages (10x Genomics).

5XFAD Tox-seq

Samples were prepared for Tox-seq analysis as previously described³¹ with the following modifications. Male and female 12-month-old 5XFAD and NTG mice were perfused with 4 °C DPBS, and cortical and hippocampal regions were dissected. Tissues were incubated with lysis buffer without ActD for 30 min at 37 °C. Using a FACS Aria II, live Sytox blue⁻ CD11b⁺ ROS⁻ and live Sytox blue⁻ CD11b⁺ ROS⁺ cell populations were sorted into tubes containing FACS buffer. Sorted cells were resuspended in 4 °C DPBS supplemented with 2% FBS and immediately processed for scRNA-seq.

For scRNA-seq library preparation, live Sytox blue⁻ CD11b⁺ ROS⁻ and live Sytox blue⁻ CD11b⁺ ROS⁺ sorted cell populations were processed using the Chromium Single Cell 3' v.2 kit following the manufacturer's instructions. Balanced library pools were sequenced across three lanes of a HiSeq 4000 system (Illumina) with a targeted sequencing depth of 100,000 reads per cell. Reads were mapped to the mm10 genome (downloaded 2019), and samples were combined and sequence-depth normalized using Cell Ranger count v.3.0.2 and aggr packages, respectively.

Brain CD11b scRNA-seq

Brains from male and female 6-month-old 5XFAD, 5XFAD:*Fgg*^{390–396A}, NTG and *Fgg*^{390–396A} mice were processed for FACS as described for 5XFAD Tox-seq analysis. Live Sytox blue[−] CD11b⁺ cells from cortical/hippocampal tissues were sorted into tubes containing DPBS supplemented with 5% FBS at 4 °C and then resuspended in 4 °C DPBS supplemented with 2% FBS at 333 cells μl^{-1} and processed for scRNA-seq with the Chromium Single Cell 3' v.3 kit following manufacturer's instructions. Balanced library pools were run across three lanes of HiSeq4000, reads mapped to the mm10 genome and samples combined and sequence-depth normalized using the Cell Ranger count v.3.0 and aggr packages, respectively.

scRNA-seq data analysis

The R toolkit Seurat⁷⁰ was used for QC, clustering analysis and differential gene expression analysis of scRNA-seq data in R v.4.0.2 unless otherwise stated. For scRNA-seq data visualizations, dittoseq package v.1 was used to produce UMAPs, dot plots and violin plots⁷¹.

For microglia scRNA-seq analysis (Fig. 2), the QC parameters were: nFeature_RNA > 1000; nFeature_RNA < 5500; and < 5% and 20% mitochondrial and ribosomal genes, respectively. nCount_RNA in the 93rd percentile (nCount_RNA < 26,206) was used for downstream analysis. Data were normalized and scaled, and a percentage of mitochondrial and cell cycle genes were regressed out using Seurat SCTransform. Jackstraw was performed with num.replicate of 100. The FindNeighbors and FindClusters functions in Seurat were used with the first eight significant principal components (PCs) and a resolution of 0.4, respectively. A total of 16,186 microglial cells passed QC, with an average of 3,469 genes per cell and 20,228 genes. Consistent with the literature⁷², canonical microglial markers were expressed at varying levels in the identified clusters (Extended Data Fig. 3e). Cluster DEGs were determined by FindAllMarkers with default parameters. Genes that met the log₂ FC threshold of >0.25 with adjusted $P < 0.05$ (Benjamini–Hochberg correction) were used for downstream analysis.

For BMDM scRNA-seq analysis (Fig. 3), two independent experiments were integrated and corrected for batch effects as previously described⁷⁰. The batch-corrected dataset QC parameters were: nFeature_RNA > 200; nFeature_RNA < 5000; and < 5% and 25% mitochondrial and ribosomal genes, respectively. The 17,625 QC-passed BMDMs were used with the Seurat integration workflow using default parameters. Jackstraw was performed with num.replicate of 100. The RunUMAP, FindNeighbors and FindClusters functions were used with the first 20 significant PCs and a resolution of 0.5. DEGs were determined by FindAllMarkers with default parameters. Genes that met the log₂ FC threshold of 0.25 with adjusted $P < 0.05$ (Benjamini–Hochberg correction) were used for downstream analysis. Pseudotime trajectories were performed on the UMAP embeddings and Seurat clusters using Slingshot v.2.2.1 (ref. 73), where cluster 3 was the predefined start point. Associations between gene expression pattern and pseudotime were tested for each lineage by fitting a negative binomial generalized additive model at 8 knots using tradeSeq v.1.8.0 (ref. 74). The estimated smoothers for each lineage accounted for batch effects. For each lineage, markers differentially expressed between the average of the start and end points of a trajectory were identified. Adjusted P values (Benjamini–Hochberg correction) were used to identify the top 50 genes for each lineage (Supplementary Table 6). To generate the heat map, a pseudocount of 1 was added to the raw scRNA-seq counts for the top 50 DEGs, the rows were log₂ row-normalized and K -means clustering was performed on the rows.

For 5XFAD Tox-seq analysis (Fig. 6), the QC parameters were 200–5,000 nFeature_RNA, <7,500 nCount_RNA, and <5% and 20% mitochondrial and ribosomal genes, respectively. Data were normalized and scaled, and a percentage of mitochondrial genes were regressed out using Seurat SCTransform. Jackstraw was performed with num.replicate of 100. FindNeighbors and FindClusters Seurat functions

were used with the first 30 significant PCs and a resolution of 0.6, respectively. To remove variation in sex-linked genes, the dataset was integrated using the Harmony algorithm⁷⁵ with runHarmony: group.by.vars = sex and assay.use = SCT. Clustering analysis was performed using Harmony dims = 15 and resolution = 0.4. In accordance with previous literature⁷⁶, all four CD11b⁺ cell clusters had high expression of core microglial genes (Extended Data Fig. 9e and Supplementary Table 13). DEGs for each cluster were determined by FindAllMarkers with default parameters using MAST statistical test. Genes that met the log₂ FC threshold of 0.25 with adjusted $P < 0.05$ (Benjamini–Hochberg correction) were used for downstream analyses.

For brain CD11b⁺ scRNA-seq analysis (Fig. 7), the QC parameters were: 1,000–4,000 nFeature_RNA, <12,000 nCount_RNA, <10% mitochondrial genes. Batch correction was performed using FindIntegrationAnchors for 'batch1' and 'batch2'. The ScaleData function was performed and microglia immediate response genes were regressed out using the vars.to.regress function set to c('Fos', 'Egr1', 'Jun', 'Junb', 'Zfp36', 'Jund', 'H3f3b', 'Btg2', 'Rhob', 'Fosb', 'Dusp1', 'Ier2', 'Socs3', 'Ier5', 'Nfkbia', 'Zfp361l', 'Btg1', 'Ptma', 'Sgk1', 'Klf6'). FindNeighbors and FindClusters were used with the first 20 significant PCs and a 0.2 resolution, respectively. Differential gene analysis was performed using FindMarkers or FindAllMarkers with MAST or Wilcoxon test for $p_{\text{val_adj}} < 0.05$ and $\text{avg_log}_2\text{FC} > 0.25$.

scRNA-seq signature enrichment

Average expression levels for a given gene list were computed across single-cell transcriptomes using the AddModuleScore function in Seurat with default parameters. The modular scores of a gene list were visualized in UMAP or violin plot. The list of genes used is provided in Supplementary Table 12.

Functional enrichment and network analysis of scRNA-seq data

Functional enrichment analysis of DEGs was performed in Metascape using default parameters⁷⁷, and significant GO terms were identified by false discovery rate (FDR) $P < 0.05$ unless otherwise stated. Gene network analyses were performed with GSEA with C5.bp.v7.1symbols.gmt using default settings. GO terms with $P < 0.10$ were used for enrichment map visualization in Cytoscape v.3.7.2 and unbiasedly clustered using the AutoAnnotate v.1.3.2 plugin with default settings. For the microglial dataset, cluster gene signatures were determined using ClusterProfiler⁷⁸ and the gseGO function with the following parameters: ont = BP, nPerm = 10000, minGSSize = 3, maxGSSize = 800, pvalueCutoff = 0.1, OrgDB = org.Mm.eg.db, pAdjustMethod = BH.

Phosphoproteomics sample preparation

RAW 264.7 macrophages (10×10^6 cells, 10 mg of protein per sample) were prepared for global phosphorylation protein sample digestion for mass spectrometry analysis as previously described⁷⁹. Macrophages were plated on fibrin-coated (final concentration, 12.5 $\mu\text{g ml}^{-1}$) or iC3b-coated (final concentration, 10 $\mu\text{g ml}^{-1}$) plates for 1 or 3 h. Fibrin concentration was based on our previous studies^{21,29,31}. We selected a comparable concentration for iC3b based on previous studies using similar concentrations for macrophage effector responses and CD11b binding⁸⁰. Under these conditions, in our previous studies, we observed phosphorylation at longer time points in primary Schwann cells⁸¹. RAW cells were used owing to the high protein concentration needed for phosphoproteomic analysis, which could not be feasibly obtained from primary BMDM cultures using instrumentation at the time of the study.

Mass spectrometry analysis

Samples were analyzed on a Thermo Scientific Orbitrap Fusion mass spectrometry system equipped with an Easy nLC 1200 uHPLC system interfaced with the mass spectrometer via a Nanoflex II nanoelectrospray source as previously described⁷⁹.

Mass spectrometry data processing and statistical analysis

Quantitative analysis was performed in R v.4.1.3. Initial QC analyses, including interrun clusterings, correlations, PCA, and peptide and protein counts and intensities were completed with the R package artMS v.1.12.0. Two sample outliers in intensities and peptide detections were discarded before quantitative analysis: fibrin 1 h (PRIDE sample ID FU20180420-23) and iC3b 1 h (PRIDE sample ID FU20180420-05). Statistical analyses of phosphorylation changes between stimulated and control runs were carried out using peptide ion fragment intensity data output from MaxQuant with preprocessing using artMS. Quantifications of phosphorylation based on peptide ions were performed with artMS::doSiteConversion and artMS::artmsQuantification with default settings using artMS⁸². All peptides containing the same set of phosphorylated sites were grouped and quantified together into phosphorylation site groups, and equal median normalization was performed across runs to control for differences in sample preparation. Statistical tests in MSstats compared phosphopeptide intensities between stimulated and control conditions for each time point. We compared each stimulation condition with its time-matched control and compared stimulations with each other (that is, fibrin versus iC3b). We used defaults for MSstats for adjusted *P* values (Student's *t* test and Benjamini–Hochberg correction), even in cases of $n = 2$ biological replicates. We quantified between 2,000 and 6,000 phosphorylated peptides per sample, mapping to 300–3,000 different proteins per sample.

Kinase activity analysis

FC values from MSstats were reduced to a single FC per site by choosing the FC with the lowest *P* value (noninfinite \log_2 -transformed FC values) and used for kinase activity and enrichment analysis. *Mus musculus* phosphorylation sites were converted to their *Homo sapiens* orthologous sites. Orthologous pairs of gene identifiers between *M. musculus* and *H. sapiens* were downloaded from Ensembl using BioMart. Ensembl gene identifiers were mapped to UniProt identifiers, and orthologous pairs of sequences were aligned using the Needleman–Wunsch global alignment algorithm implemented using the Biostrings v.2.62.0 function pairwiseAlignment with default parameters in R. The resulting alignments were used to convert the sequence positions of phosphorylations in *M. musculus* to positions in *H. sapiens* protein sequences, if possible. Kinase activities were estimated using known kinase–substrate relationships⁸³ and inferred as a *z* score calculated using the mean \log_2 FC of phosphorylated substrates for each kinase in terms of standard error ($z = (M - u)/s.e.$), comparing FCs in phosphosite measurements of the known substrates against the overall distribution of FCs across the sample. *P* values were calculated using two-tailed *z* test⁸⁴. We collected substrate annotations for 400 kinases with available data. Kinases with two or more measured substrates were considered to be predicted kinases (Supplementary Table 11).

Network reconstruction and enrichment analysis of phosphoproteomics data

Proteins with changes in phosphorylation state were selected based on an FDR threshold of 0.05. Protein phosphorylation site pairs significant for at least one time point were maintained. After filtering, iC3b resulted in 44 phosphoproteins, and fibrin resulted in 68 phosphoproteins. The STRING database was queried using Cytoscape. Proteins with STRING interaction scores higher than 0.4 were connected by edges with widths and opacities reflecting the score level. Phosphorylation state changes were visualized using Omics Visualizer⁸⁵ as two outer ring circles representing phosphorylation at 1 h and 3 h. To enhance the signal, we included up to ten additional nodes identified by the STRING database as functionally related to our phosphoproteins using stringApp⁸⁶. Final results were filtered based on an FDR threshold of 0.05, and redundant results were removed using a redundancy cutoff of 0.5. Two significant GO terms were selected and visualized as node

fill colors. STRING-provided proteins and unconnected proteins were removed for visualization.

Fibrin phosphorylation cell assays

BMDMs were cultured for 18 h in RPMI-1640 supplemented with 1% FBS (RPMI 1% FBS). Cells were plated on fibrin-coated dishes for 15–90 min in RPMI 1% FBS and then processed for either immunocytochemistry (ICC) or immunoblotting. Unstimulated BMDMs served as controls. Primary rat microglia were used on day 4 in vitro and plated on fibrin-coated dishes for 15–75 min in DMEM supplemented with 2% FBS. Unstimulated microglia served as controls.

Pharmacologic inhibition assays

BMDMs were cultured for 18 h in RPMI-1640 supplemented with 1% serum. For MEK inhibition, cells were preincubated with 20 nM trametinib (S2673, Selleckchem) for 2 h and then plated on fibrin-coated plates for 90 min for ICC or 6 h for quantitative PCR. Cells unstimulated in RPMI 1% FBS for 90 min or 6 h were used as time point zero controls. Dimethyl sulfoxide was used as a vehicle control. Fibrin–CD11b blockade using 5B8 monoclonal antibody was performed as previously described²⁹. In brief, 5B8 or IgG2b isotype control antibodies were preincubated (each 50 $\mu\text{g ml}^{-1}$) in fibrin-coated plates for 90 min at 37 °C before cell plating. Cells were incubated on fibrin for 90 min and processed for ICC. Cells incubated with 5B8 or IgG2b in the absence of fibrin served as controls.

Immunohistochemistry and Immunocytochemistry

Brains were processed for immunohistochemistry as described^{29,31}. The following antibodies were used: mouse anti-GP91phox (1:150; 53, BD Biosciences), rabbit anti-IBA1 (1:500; 019-19741, Wako), goat anti-APOE (1:50; AB947, MilliporeSigma), and Alexa 647, 488 and Cy3 (1:500; Jackson ImmunoResearch). Amyloid plaques were labeled with 5 mg/mL Methoxy-X04 (Tocris) for 30 min at 23 °C. Confocal images were acquired with a Fluoview FV1000 (Olympus) confocal microscope and Fluoview software v.3.1b with Olympus x40 and 0.8 NA water-immersion lens. Images of the CA3 hippocampus and periplaque were quantified using NIH ImageJ (v.1.50). Image acquisition and quantification was performed by observers blinded to experimental conditions.

ICC was performed as previously described⁸⁷ with the following modifications. Briefly, BMDMs were seeded into 16-well chamber glass slides (Nunc) coated with fibrin for various times in a 5% CO₂ incubator at 37 °C. Cells were allowed to adhere for 15–30 min before time point collection. Cells unstimulated in RPMI 1% FBS overnight were used as time point zero controls unless otherwise stated. Primary antibodies for p-NCF2 (1:500, rabbit polyclonal, PA5-I05094, Thermo Fisher Scientific), p-PXN (1:500, rabbit polyclonal, PAB7932, Abnova) and p-MEK2 (1:500, rabbit polyclonal, 28955-1-AP, Thermo Fisher Scientific) were incubated overnight at 4 °C. Actin was stained with Alex Fluor Plus 555 Phalloidin, and nuclei were visualized with DAPI following the manufacturer's instructions (Thermo Fisher Scientific). Images were acquired with an Axioplan II epifluorescence microscope (Zeiss) as previously described³¹, or Z stack images were taken with an LSM880 confocal microscope (Zeiss) using a $\times 63$ objective. Image quantification was performed as previously described^{66,87}. In ImageJ, a cell mask was created using phalloidin staining, then immunoreactivity was measured within the mask using the same threshold across images and presented as a percentage area.

Immunoblots

Immunoblot analysis was performed as previously described²⁹ with the following sample preparation specification. Primary microglia were washed in 4 °C DPBS and then incubated in Pierce RIPA lysis buffer supplemented with 1 \times Halt Protease and phosphatase inhibitors (complete RIPA; Thermo Fisher Scientific) for 15 min at 4 °C. For brain samples,

cortices were dissected from PBS-perfused 12-month-old male and female mice. Tissues were incubated in complete RIPA for 30 min at 4 °C. Primary antibodies were: p-NCF2 (1:1000, rabbit polyclonal, PA5-105094, Thermo Fisher Scientific); NCF2 (1:1000, rabbit polyclonal, PA5-37323, Thermo Fisher Scientific), p-PXN (1:1000, rabbit polyclonal, PAB7932, Abnova), paxillin (1:1000, rabbit monoclonal, ab32115, Abcam), p-MEK2 (1:1000, rabbit polyclonal, 28955-1-AP, Thermo Fisher Scientific), MEK1/2 (1:10,000, rabbit monoclonal, ab178876, Abcam) and GAPDH (1:10,000, rabbit monoclonal, 2118, Cell Signaling Technology). Primary antibodies were visualized with horseradish peroxidase-conjugated secondaries (Cell Signaling Technology) and ECL reagents. Densitometry was performed using NIH ImageJ (v.1.50), with protein values for each band normalized to GAPDH from the same membrane.

Quantitative real-time PCR

Quantitative PCR and data analysis were performed as previously described³¹. The following primer sequences were used. *Gapdh*: forward, caaggccgagaatgggaag; and reverse, ggctcacccttgatgt. *Ill1b*: forward, agttgacggaccccaaaag; and reverse, agctggatgctctcatcagg.

Statistical analyses for nonsequencing data

Data are presented as mean ± s.e.m. with overlaid scatter plot. Data distribution was assumed to be normal, but this was not formally tested. Two-tailed unpaired *t* test or Mann–Whitney test, one-way analysis of variance (ANOVA) and two-way ANOVA tests were performed with GraphPad Prism v.9. No statistical method was used to predetermine sample sizes, but sample sizes were similar to those used in our previously published studies^{29,31}. All mice survived until the end of the study, and all of the data were analyzed. Mice were randomized and blindly coded for group assignment and data collection for immunohistochemistry and ICC experiments. For in vivo stereotactic plasma injections, mice were randomized and blindly coded for group assignment and data collection. For all scRNA-seq experiments, mice were randomized by sex and genotype before sample preparation. All injections, histological analyses and quantification were done in a blinded fashion. Quantification of immunohistochemistry data was performed independently by two blinded observers.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The scRNA-seq and bulk RNA-seq datasets are deposited in the Genome Expression Omnibus under SuperSeries accession number [GSE229376](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE229376). Searchable web resources from this study of the microglia and BMDM ligand-activation scRNA-seq data are available at https://toxseq.shinyapps.io/ligand_activation/, and the single-cell 5XFAD Tox-seq data are available at https://toxseq.shinyapps.io/5xfad_toxseq/. The EAE Tox-seq data are available at https://toxseq.shinyapps.io/scrnaseq_viewer/. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier [PXD021230](https://doi.org/10.18119/N91S5X). The phosphoproteomic interaction networks have been made available through NDEx at <https://doi.org/10.18119/N9F317> (fibrin network), <https://doi.org/10.18119/N91S5X> (iC3b network), <https://doi.org/10.18119/N95K6G> (fibrin GO-enriched subnetwork) and <https://doi.org/10.18119/N9990P> (iC3b GO-enriched subnetwork). Source data are provided with this paper.

References

61. Oakley, H. et al. Intraneuronal β -amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* **26**, 10129–10140 (2006).
62. Suh, T. T. et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. *Genes Dev.* **9**, 2020–2033 (1995).
63. Flick, M. J. et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor $\alpha_M\beta_2$ /Mac-1 is critical for host inflammatory response in vivo. *J. Clin. Invest.* **113**, 1596–1606 (2004).
64. Wessels, M. R. et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. *Proc. Natl Acad. Sci. USA* **92**, 11490–11494 (1995).
65. Roopenian, D. C. et al. Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. *MAbs* **7**, 344–351 (2015).
66. Petersen, M. A. et al. BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis. *Brain* **144**, 2291–2301 (2021).
67. Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat. Biotechnol.* **38**, 276–278 (2020).
68. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 (2003).
69. Szklarczyk, D. et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.* **49**, D605–D612 (2021).
70. Stuart, T. et al. Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902.e1821 (2019).
71. Bunis, D. G., Andrews, J., Fragiadakis, G. K., Burt, T. D. & Sirota, M. dittoSeq: universal user-friendly single-cell and bulk RNA sequencing visualization toolkit. *Bioinformatics* **36**, 5535–5536 (2021).
72. Hammond, T. R. et al. Single-Cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. *Immunity* **50**, 253–271.e256 (2019).
73. Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. *BMC Genomics* **19**, 477 (2018).
74. Van den Berge, K. et al. Trajectory-based differential expression analysis for single-cell sequencing data. *Nat. Commun.* **11**, 1201 (2020).
75. Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat. Methods* **16**, 1289–1296 (2019).
76. Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* **160**, 1061–1071 (2015).
77. Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**, 1523 (2019).
78. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* **16**, 284–287 (2012).
79. Johnson, J. R. et al. Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling. *Cell Rep.* **39**, 110690 (2022).
80. Takizawa, F., Tsuji, S. & Nagasawa, S. Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. *FEBS Lett.* **397**, 269–272 (1996).
81. Akassoglou, K., Yu, W.-M., Akpinar, P. & Strickland, S. Fibrin inhibits peripheral nerve regeneration by arresting Schwann cell differentiation. *Neuron* **33**, 861–875 (2002).
82. Choi, M. et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. *Bioinformatics* **30**, 2524–2526 (2014).
83. Bachman, J. A., Gyori, B. M. & Sorger, P. K. Assembling a corpus of phosphoproteomic annotations using ProtMapper to normalize site information from databases and text mining. Preprint at <https://www.biorxiv.org/content/10.1101/822668> (2022).

84. Hernandez-Armenta, C., Ochoa, D., Goncalves, E., Saez-Rodriguez, J. & Beltrao, P. Benchmarking substrate-based kinase activity inference using phosphoproteomic data. *Bioinformatics* **33**, 1845–1851 (2017).
85. Legeay, M., Doncheva, N. T., Morris, J. H. & Jensen, L. J. Visualize omics data on networks with Omics Visualizer, a Cytoscape app. *F1000Res* **9**, 157 (2020).
86. Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: network analysis and visualization of proteomics data. *J. Proteome Res.* **18**, 623–632 (2019).
87. Petersen, M. A. et al. Fibrinogen activates BMP signaling in oligodendrocyte progenitor cells and inhibits remyelination after vascular damage. *Neuron* **96**, 1003–1012.e1007 (2017).

Acknowledgements

We thank the Gladstone Genomics Core (N. Carli, J. McGuire and M. Bernardi) for library preparation; CZ Biohub Sequencing Core (N. Neff, R. Sit and M. Tan) and UCSF CAT Core for sequencing support; K. Claiborn for editorial assistance; and G. Maki for graphics. Gladstone Institutes was supported by the NIH/NCRR C06 RR018928 grant. This research was supported by NMSS Postdoctoral Fellowship FG-1708-28925, UCSF Immunology NIH/NIAID T32 AI007334, the Berkelhammer Award for Excellence in Neuroscience and an NIH/NINDS K99 NS126707 to A.S.M.; a BrightFocus Foundation Fellowship A2021019F to Z.Y.; the NIH/NIAID K99 AI163868 to M.B.; and the Ray and the Dagmar Dolby Family Fund, the Simon Family Trust, and NIH/NIA RF1 AG064926 and NIH/NINDS R35 NS097976 to K.A.

Author contributions

A.S.M. designed and performed experiments, led bioinformatic analysis and analyzed data. Z.Y. performed experiments and analysis related to Tox-seq studies. A.S.M., J.R.J. and M.B. performed phosphoproteomic experiments and analyzed data. M-G.S. and A.R.P. analyzed phosphoproteomics data and performed network analysis. A.A. performed bioinformatic analyses and developed Shiny R applications. K.D., A.M.-F., Y.Y., E.M., G.M., C.P., N.A., B.C., R.M.-A. and M.D.P.A. performed experiments. S.Z. designed

experiments. J.K.R. designed and performed experiments. N.J.K. designed phosphoproteomic experiments. K.A. conceived the project, designed the study and analyzed data. A.S.M. and K.A. wrote the manuscript with input from all authors.

Competing interests

K.A. is the scientific founder, advisor and shareholder of Therini Bio, Inc. Her interests are managed by Gladstone Institutes according to its conflict of interest policy. The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. has financially compensated consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, Interline Therapeutics, Rezo Therapeutics, GEn1E Lifesciences, Inc. and Twist Bioscience Corp. He is on the Board of Directors of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics and Interline Therapeutics.

Additional information



Extended data is available for this paper at <https://doi.org/10.1038/s41590-023-01522-0>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41590-023-01522-0>.


Correspondence and requests for materials should be addressed to Katerina Akassoglou.

Peer review information *Nature Immunology* thanks the anonymous reviewers for their contribution to the peer review of this work. L. A. Dempsey was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Blood-innate immunity multiomics pipeline. a, Blood-innate immunity multiomics pipeline for identification of blood-induced immune pathways and in vivo validation studies. **b**, Gating strategy for blood-induced microglia transcriptomic profiling.




Extended Data Fig. 2 | RNA-seq analysis of microglia from plasma injected brains. a-d, Volcano plots of DEGs from RNA-seq analysis of sorted microglia from plasma or aCSF injected brains. Comparisons between DEGs in microglia from *Alb*^{-/-} plasma vs aCSF (**a**), *C3*^{-/-} plasma vs aCSF (**b**), *Alb*^{-/-} plasma vs WT plasma

(**c**) or *C3*^{-/-} plasma vs WT plasma (**d**) injected brains are shown. Dots depict average \log_2 FC and $-\log_{10}$ adjusted P values ($|\log_2| > 0.5$, adjusted P value < 0.1 with Wald test followed by Benjamini-Hochberg multiple test correction). Data are from $n = 6$ *Fga*^{-/-}, $n = 6$ WT, $n = 6$ aCSF, $n = 8$ *Alb*^{-/-} mice.

**Extended Data Fig. 3 | Blood-induced microglial gene co-expression network.**

Top, Co-expression gene network of 196 DEGs upregulated in microglia by WT plasma compared to aCSF control. Bottom, overlay of blood gene network with microglial gene expression values from *Fga*^{-/-} plasma-treated mice. Red shading,


genes upregulated in microglia; blue shading, genes downregulated in microglia; the orange border indicates significance of $P < 0.1$ (Wald test followed by Benjamini-Hochberg multiple test correction). Data are from $n = 3$ biological replicates per group, with two mice pooled per replicate.



Extended Data Fig. 4 | See next page for caption.


Extended Data Fig. 4 | Quality control for primary microglia scRNA-seq and BMDM scRNA-seq datasets. a, b, Violin plots of number genes (**a**) and unique molecular identifiers (UMI, **b**) per cell post-normalization and shown for each biologically independent sample from scRNA-seq of primary microglia stimulated with fibrin, iC3b, LPS or left unstimulated. Data are from two biologically independent samples of fibrin, two biologically independent samples of iC3b, two biologically independent samples of LPS, and one biologically independent sample of unstimulated primary microglia. **c**, Elbow plot of top PC used to select for clustering analysis. **d**, Distribution of cells in each biologically independent sample across each seurat clusters. **e**, Dot plot of selected microglial gene markers across each cluster from scRNA-seq dataset of primary microglia as shown in Fig. 3a. Average gene expression and cell population expression is depicted as log expression and percent, respectively.

f, g, Violin plots of number genes (**f**) and UMI (**g**) per cell post-normalization and shown for each biologically independent sample from scRNA-seq of primary BMDMs stimulated with fibrin, iC3b, LPS or left unstimulated. Data are from three biologically independent samples of fibrin, one biologically independent sample of iC3b, two biologically independent samples of LPS and four biologically independent samples of unstimulated BMDMs. **h**, Elbow plot of top PC used to select for clustering analysis. **i**, Distribution of cells in each biologically independent sample across each seurat clusters. **j**, Gene-set enrichment plots of top GO terms for a given cluster (adjusted P value < 0.05 with BH correction). Violin plots depict minimum, maximum, and median expression, with points showing single-cell expression levels (**a, b, f, g**). Box plots show the 1st to 3rd quartiles (25–75% box bounds) with median values indicated and upper and lower whiskers extending to 1.5*inter-quartile range (**a, b, f, g**).




Extended Data Fig. 5 | Pseudotime trajectory analysis of scRNA-seq BMDM profiles. a, UMAP plots of BMDM scRNA-seq profiles colored by treatment (left) or cluster (right) as shown in Fig. 3a, overlaid with pseudotime trajectory analysis with Slingshot. Black arrows indicate inferred trajectories with unstimulated (cluster 3) defined as starting point. **b**, Heat map of single cell gene expression

patterns across pseudotime trajectories of top 50 DEGs. **c**, Dot plot of selected macrophage gene markers across each cluster from scRNA-seq datasets of primary BMDMs as shown in Fig. 3a. Average gene expression and cell population expression is depicted as log expression and percent, respectively.




Extended Data Fig. 6 | Network analysis and functional validation of phosphoproteomic dataset. **a**, \log_2 intensity of phosphorylated peptides (rows) for each biological replicate (columns) across stimulation comparisons at each time point. Cells colored white indicate not detected. Unstimulated, US. Data from $n=2$ (Fibrin 1 h), $n=2$ (iC3b 1 h), $n=3$ (US 1 h), $n=3$ (Fibrin 3 h), $n=3$ (iC3b 3 h), $n=3$ (US 3 h) independent experiments. **b**, \log_2 FC of phosphorylated peptides between fibrin vs US and iC3b vs US at each timepoint. **c**, UpSet plot showing a matrix layout of DEPs specific to a treatment (single filled circle with no vertical lines) or shared between treatment (filled circles connected with vertical lines) comparisons. Bar plots of the unique or overlapping DEPs in treatment comparison (top) and the number DEPs for each treatment comparison (left). Phosphorylation sites considered DEPs (FDR < 0.05 and $\text{abs}(\log_2 \text{FC}) > 1.5$) are

shown. Student's *t*-test with BH correction. **d**, Phosphoproteomic GO network for fibrin or iC3b. Phosphorylation changes ($\log_2 \text{FC}$) depicted as blue-red scheme and timepoint (h) as rings. GO terms indicated by node fill color and protein interaction strength as edge thickness and opacity. **e**, Confocal microscopy of p-MEK2 staining in BMDMs left unstimulated or stimulated for 90 min with fibrin alone or in the presence of trametinib. Nuclei labeled with DAPI. Scale bar, 50 μm . Quantification of p-MEK2 for $n=3$ independent experiments in duplicates. $P < 0.05$ as determined by two-tailed unpaired *t*-test. **f**, Quantitative PCR of *Il1b* expression in BMDMs unstimulated or stimulated for 6 h with fibrin alone or in the presence of trametinib. Data are from $n=3$ independent experiments performed in duplicates. $P < 0.05$ as determined by one-way ANOVA with Tukey's multiple comparisons test.



Extended Data Fig. 7 | A model of fibrin-induced signal transduction in macrophages. Fibrin binding to CD11b-CD18 leads to the conversion of the integrin to the high-affinity extended-open (active) conformation that induces signal transduction in macrophages. This outside-in signaling is propagated by the formation of focal adhesions through recruitment and phosphorylation of scaffold proteins and signaling kinases such as paxillin and focal adhesion kinase (FAK) resulting in phosphorylation of PI3K and cytoskeleton organization. In parallel, the MAPK cascade MEK2 and ERK1/2 components are phosphorylated


leading to 1) transactivation of NADPH oxidase complex (NOX2) and mitochondria responses to induce ROS release and oxidative stress, 2) phosphorylation of SMARCA5, NUP98, and the ERK1/2 nuclear transporter RANBP3 to regulate nuclear import, 3) phosphorylation of IRF2B2 regulating IFN signaling and 4) transcriptional activation of fibrin-induced genes involved in inflammatory, oxidative stress, and IFN-I responses. Phosphorylation (P); fibrin-induced proteins identified in this study, red filled shapes; fibrin-induced genes identified in this study are shown in box. Created with Biorender.com.



Extended Data Fig. 8 | See next page for caption.

Extended Data Fig. 8 | Ligand-induced profile overlays with EAE innate immune cell signatures, and quality control data related to Fig. 6. a, Dot plot of selected gene markers across scRNA-seq datasets of primary microglia or BMDMs unstimulated or stimulated with fibrin, iC3b, or LPS. Gene expression is depicted as scaled log-normalized expression. **b**, Violin plot of primary microglia overlaid with microglial homeostatic gene signature from healthy mice as previously identified³¹. Treatments in x-axis are rank ordered from highest to lowest expression. $P < 0.0001$ by one-way ANOVA with Tukey's multiple comparison test. **c**, Flow cytometry plots of live CD11b⁺ROS⁻ and live CD11b⁺ROS⁺ cells from brains of 12-month-old 5XFAD and NTG mice. Cell population (%) shown inside plot. Data representative of two independent experiments. **d**, Quantification of total live CD11b⁺ cells and CD11b⁺ROS⁺ cells from brains of 12m 5XFAD and NTG mice. Data from $n = 3$ mice per genotype shown as mean \pm s.e.m. ROS production assessed via DCFDA (**c,d**). $P < 0.05$ as determined by


two-tailed, unpaired t-test with Welch's correction. **e, f**, Violin plots of number genes (**e**) and UMI (**f**) per cell post-normalization, shown for each biologically independent sample for 5XFAD and NTG Tox-seq analysis. Data from $n = 3$ mice per condition. Box plots show the 1st to 3rd quartiles (25–75% box bounds) with median values indicated and upper and lower whiskers extending to 1.5 \times interquartile range. **g**, UMAP plots as shown in Fig. 6a overlaid with microglial gene marker expression. Expression depicted as log-fold change expression. **h**, Heat map of top DEGs per single cell cluster from 5XFAD Tox-seq dataset. Gene expression depicted as scaled z-score. **i**, Volcano plot of DEGs in microglia between CD11b⁺ROS⁺ compared to CD11b⁺ROS⁻ cells in NTG mice. Dots depict average \log_2 FC and $-\log_{10}$ adjusted P values ($\log_2 > 0.25$, adjusted P value < 0.05 , MAST test with BH correction). Violin plots depict minimum, maximum, and median expression, with points showing single-cell expression levels (**b, e, f**).



Extended Data Fig. 9 | Quality control for scRNA-seq data related to Fig. 7.

a, Violin plots of gene counts, UMI counts, and %mito for each biologically independent sample. F, female; M, male. **b**, Violin plots of cell type marker genes used to annotate each cluster. **c**, Cluster ratio per biological replicate. **d**, UMAP

plot of all single CD11b+ cells identified by clustering analysis ($n = 9,286$ cells from brains of three 5XFAD, three NTG, four 5XFAD:*Fgg*^{390-396A}, and four *Fgg*^{390-396A} mice). **e**, UMAP plots of microglial cells subclustering analysis split by genotype. Ven diagrams depict percentage of cells per cluster.



Extended Data Fig. 10 | See next page for caption.

Extended Data Fig. 10 | Pathway analysis of unique microglia oxidative stress gene signatures and gene signature overlays. **a**, Metascape analysis showing the top significant gene pathways shared in ROS⁺ microglia from EAE (top) and 5XFAD (bottom) mice. Data correspond to gene signatures in Fig. 8b. *P* values calculated by hypergeometric test without multiple test correction. **b, c**, Dot plot

of microglia gene expression from plasma or control injected brains overlaid with microglia fibrin and iC3b/fibrin activation signature genes (**b**) or in vivo DAM signature (**c**). Data points represent the average of $n = 3 - 4$ biological replicates per group. Two mice were pooled per replicate. Significance determined by Wald test following by BH test correction.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Single cell transcriptomes were prepared using 10X Genomics Chromium Controller and sequenced using Illumina Novaseq6000 and HiSeq4000. Cells were sorted using BD Biosciences FACSAria II with BD FACSDiva v8 and analyzed with FlowJo software v10. Proteomics was performed on a thermo Scientific Orbitrap Fusion mass spectrometry system equipped with an Easy nLC 1200 uHPLC system interfaced with the mass spectrometer via a Nanoflex II nanoelectrospray source. BD FACSDiva v8 and FlowJo software v10 were used.

Data analysis

Bulk RNA-seq of microglia. To facilitate reproducible RNA-seq data analysis, samples were processed using the open-access Nextflow RNA-seq pipeline⁵⁹ using nextflow v20.12.0-edge in Singularity with default nf-core/rnaseq v3.0 parameters for paired-end FASTQ files. The following packages were used: Bioconductor-summarized experiment v1.20.0; bedtools v2.29.2; deseq2 v 1.28.0; dupradar v1.18.0; fastqc v0.11.9; picard v2.23.9; preseq v2.0.3; rseqc v3.0.1; salmon v.1.4.0; samtools v1.10; star v2.6.1d; stringtie v2.1.4; subread 2.0.1, trimgalore v0.6.6 and ucsc v377. FASTQ files were mapped to GRCm38/mm10 genome (downloaded from nf-core). Gene analyses was performed in R v4.2.0 using DeSeq2 v1.36.0 on the salmon.merged.gene_counts_scaled file produced by Nextflow. Reads with fewer than 3 counts per gene across replicates were filtered out. One outlier sample from groups Fga^{-/-}, WT, Fggy390-396A and aCSF were removed from downstream analyses due to large deviation in PCA and poor sequence alignment. For differential gene analysis the results function in DeSeq2 was used with contrast to test between two genotypes and treatments of interest. The results were then filtered for significance using \log_2 foldchange > 0.5 and padj < 0.1 unless otherwise stated. KEGG analysis was performed using clusterProfiler v4.4.4 with default parameters and pvalueCutoff set to 0.1. The blood microglia gene network was generated and visualized in Cytoscape v3.7.260 using upregulated DEGs identified between WT plasma compared to aCSF samples (Supplementary Table 3). GO pathways were determined using functional enrichment analysis in String package⁶¹ with default parameters visualized in Cytoscape.

scRNA-seq data analysis. The R toolkit Seurat was used for QC, clustering analysis, and differential gene expression analysis of scRNA-seq data and performed in R v.4.0.2 unless otherwise stated. For scRNA-seq data visualizations, dittoseq package v1 was used to produce UMAPs, dot plots, and violin plots⁷³.

For microglia scRNA-seq analysis (Fig. 2), QC parameters were: nFeature_RNA > 1000; nFeature_RNA < 5500; < 5% and 20% mitochondrial and ribosomal genes, respectively. nCount_RNA in the 93rd percentile (nCount_RNA < 26,206) were used for downstream analysis. Data were

normalized, scaled, and percent of mitochondrial and cell cycle genes regressed out following Seurat SCTransform. Jackstraw was performed with num.replicate of 100. FindNeighbors and FindClusters functions in Seurat were used with the first 8 significant PCs and a resolution of 0.4 resolution, respectively. 16,186 microglial cells passed QC with an average of 3,469 genes per cell with 20,228 genes. Consistent with literature, canonical microglial markers were expressed at varying levels in the identified clusters (Extended Data Fig. 3e). Cluster DEGs were determined by FindAllMarkers with default parameters. Genes that met $\log_2\text{fc.threshold} > 0.25$ with adjusted P value < 0.05 (Benjamini-Hochberg correction) were used for downstream analysis.

For BMDM scRNA-seq analysis (Fig. 3), two independent experiments were integrated and corrected for batch effect as described. Batch-corrected dataset QC parameters were: nFeature_RNA > 200 ; nFeature_RNA < 5000 ; $< 5\%$ and 25% mitochondrial and ribosomal genes, respectively. 17,625 QC-passed BMDMs were used with Seurat integration workflow using default parameters. Jackstraw was performed with num.replicate of 100. RunUMAP, FindNeighbors and FindClusters functions were used with the first 20 significant PCs and a resolution of 0.5. DEGs were determined by FindAllMarkers with default parameters. Genes that met $\log_2\text{fc.threshold}, 0.25$ with adjusted P value < 0.05 (Benjamini-Hochberg correction) were used for downstream analysis. Pseudotime trajectories were performed on the UMAP embeddings and Seurat clusters using Slingshot v2.2.175, where cluster 3 was the predefined start point. Associations between gene expression pattern and pseudotime were tested for each lineage by fitting a negative binomial generalized additive model at 8 knots using tradeSeq v1.8.076. The estimated smoothers for each lineage accounted for batch effects. For each lineage, markers differentially expressed between the average of the start and end points of a trajectory were identified. Adjusted P value (Benjamini-Hochberg correction) was used to identify the top 50 genes for each lineage (Supplementary Table 6). To generate the heatmap, a pseudocount of 1 was added to the raw single cell RNA-seq counts for the top 50 DEGs, the rows were \log_2 row-normalized and K-means clustering was performed on the rows.

For the 5XFAD Tox-seq analysis (Fig. 6), QC parameters were 200 – 5,000 nFeature_RNA, $< 7,500$ nCount_RNA, $< 5\%$ and 20% mitochondrial and ribosomal genes, respectively. Data were normalized, scaled and percent of mitochondrial genes regressed out following Seurat SCTransform. Jackstraw was performed with num.replicate of 100. FindNeighbors and FindClusters Seurat functions were used with the first 30 significant PCs and a resolution of 0.6 resolution, respectively. To remove variation in sex-linked genes, the dataset was integrated with Harmony algorithm with runHarmony: group.by.vars = sex and assay.use = SCT. Clustering analysis was performed using Harmony dims = 15 and resolution = 0.4. In accordance with prior literature⁷⁸, all four CD11b+ cell clusters had high expression of core microglial genes (Extended Data Fig. 8e and Supplementary Table 13). DEGs for each cluster were determined by FindAllMarkers with default parameters using MAST statistical test. Genes that met $\log_2\text{fc.threshold}, 0.25$ with adjusted P value < 0.05 (Benjamini-Hochberg correction) were used for downstream analyses.

For brain CD11b+ scRNA-seq analysis (Fig. 7), QC parameters were: 1,000 – 4,000 nFeature_RNA, $< 12,000$ nCount_RNA, $< 10\%$ mitochondrial genes. Batch correction was performed using FindIntegrationAnchors for “batch1” and “batch2”, ScaleData function was performed on integrated object regression out known microglia immediate response genes. The vars.to.regress function was set to c(‘Fos’, ‘Egr1’, ‘Jun’, ‘Junb’, ‘Zfp36’, ‘Jund’, ‘H3f3b’, ‘Btg2’, ‘Rhob’, ‘Fosb’, ‘Dusp1’, ‘Ier2’, ‘Socs3’, ‘Ier5’, ‘Nfkbia’, ‘Zfp361’, ‘Btg1’, ‘Ptma’, ‘Sgk1’, ‘Klf6’). FindNeighbors and FindClusters were used with the first 20 significant PCs and a 0.2 resolution, respectively. Differential gene analysis was performed using FindMarkers or FindAllMarkers with MAST or Wilcoxon test for $p_{\text{val_adj}} < 0.05$ and $\text{avg_log}_2\text{FC} > 0.25$.

scRNA-seq signature enrichment. The average expression levels of a given gene list was computed across single-cell transcriptomes using the AddModuleScore function in Seurat with default parameters. The modular scores of a gene list (i.e., signature enrichment) were visualized in UMAP or violin plot. The list of genes used are provided in Supplementary Table 12.

Functional enrichment and network analysis of scRNA-seq data. For in vitro datasets, functional enrichment analysis of DEGs was performed in Metascape using default parameters⁶⁹, and significant GO terms were identified by FDR P value < 0.05 unless otherwise stated. Gene network analyses were performed with GSEA with molecular signatures database biological process for GO (C5.bp.v7.1symbols.gmt) using default settings. GO terms with P value < 0.10 were used for Enrichment Map Visualization in Cytoscape v.3.7.2 and were unbiasedly clustered using the plugin AutoAnnotate v. 1.3.2 with default settings. For the microglial dataset, cluster gene signatures were determined using ClusterProfiler v4.4.4 and gseGO function with the following parameters: ont = BP, nPerm = 10000, minGSSize = 3, maxGSSize = 800, pvalueCutoff = 0.1, OrgDB = org.Mm.eg.db, pAdjustMethod = BH.

Mass spectrometry data processing and statistical analysis. Quantitative analysis was performed in the R v.4.1.3. Initial quality control analyses, including inter-run clusterings, correlations, principal component analysis (PCA), peptide and protein counts and intensities were completed with the R package artMS v1.12.0. Two sample outliers in intensities and peptide detections were discarded prior to quantitative analysis: Fibrin 1 h (PRIDE sample ID FU20180420-23) and one iC3b 1 h (PRIDE sample ID FU20180420-05) samples. Statistical analysis of phosphorylation changes between stimulated and control runs were computed using peptide ion fragment intensity data output from MaxQuant and pre-processed using artMS. Quantifications of phosphorylation based on peptide ions were processed using artMS as a wrapper around MSstats86, via functions artMS::doSiteConversion and artMS::artmsQuantification with default settings. All peptides containing the same set of phosphorylated sites were grouped and quantified together into phosphorylation site groups and equalize median normalization was performed across runs to control for differences in sample preparation. Next, we performed statistical tests in MSstats to compare phosphopeptide intensities between stimulated and control conditions for each time point. We compared each stimulation condition to its time-matched control and also directly compared stimulations to each other (i.e., Fibrin vs. iC3b). We used defaults for MSstats for adjusted P values, even in cases of $n=2$ biological replicates. By default, MSstats uses the Student’s t-test for P value calculation and the Benjamini-Hochberg method of FDR estimation to adjust P values. On average, we quantified between 2,000-6,000 phosphorylated peptides per sample, mapping to 300-3,000 different proteins per sample.

Kinase activity analysis of phosphoproteomics data. Fold changes from MSstats were reduced to a single fold change per site by choosing the fold change with the lowest P value (non-infinite \log_2 -transformed fold change values) and used for kinase activity and enrichment analysis. Mus musculus phosphorylation sites were converted to their Homo sapiens orthologous sites. Orthologous pairs of gene identifiers between M.musculus and H.sapiens were downloaded from Ensembl using the BioMart. Ensembl gene identifiers were mapped to UniProt identifiers and orthologous pairs of sequences were aligned using the Needleman-Wunsch global alignment algorithm implemented using Biostings v2.62.0 function pairwiseAlignment with default parameters in R. The resulting alignments were used to convert the sequence positions of phosphorylations in M.musculus to positions in H.sapiens protein sequences, if possible. Kinase activities were estimated using known kinase-substrate relationships and inferred as a z-score calculated using the mean $\log_2\text{FC}$ of phosphorylated substrates for each kinase in terms of standard error ($z = (M - u) / s.e.$), comparing fold changes in phosphosite measurements of the known substrates against the overall distribution of fold changes across the sample. P values were calculated using a two-tailed z-test. We collected substrate annotations for 400 kinases with available data. Kinases with 2 or more measured substrates were considered as predicted kinases (Supplementary Table 11).

Network reconstruction and enrichment analysis of phosphoproteomics data. Proteins with changes in phosphorylation state were selected based on an FDR threshold of 0.05. To compare phosphorylation status at two time points, 1 h and 3 h, protein-phosphorylation site pairs that

were found to be significant at least at one time point were maintained. After filtering, iC3b resulted in 44 phosphoproteins, and fibrin resulted in 68 phosphoproteins. To investigate the functional relatedness of proteins, STRING database was queried using the network analysis tool Cytoscape. Proteins with STRING interaction scores higher than 0.4 were connected by edges with widths and opacities reflecting the score level. Phosphorylation state changes were visualized using Omics Visualizer as two outer ring circles, with each layer representing phosphorylation at 1 h and 3 h. In order to enhance the signal for enrichment analysis, we also included up to ten additional nodes (proteins) identified by the STRING database as functionally related to our phosphoproteins using the stringApp. Final results are filtered based on an FDR threshold of 0.05 and redundant results were removed using a redundancy cutoff of 0.5. Two significant Gene Ontology (GO) Biological Process terms were selected and visualized as node fill colors. STRING-provided proteins and unconnected proteins were removed for visualization.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The scRNA-seq and bulk RNA-seq datasets are deposited in the Genome Expression Omnibus under the SuperSeries accession number GSE229376. A searchable web resource of the microglia and BMDM ligand-activation scRNA-seq data are available at https://toxseq.shinyapps.io/ligand_activation/ and the single-cell 5XFAD Tox-seq data at https://toxseq.shinyapps.io/5xfad_toxseq/. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD021230. The protein interaction networks have been made available through NDEx at <https://doi:10.18119/N9CK5Z> and <https://doi:10.18119/N9H89M>.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to pre-determine sample sizes but sample sizes are similar to our previous publications (Ryu et al., Nat Immunol., 19, 1212-1223 (2018); Mendiola et al. Nat Immunol., 21, 513-524 (2020).
Data exclusions	From bulk RNA-seq experiment, three samples were removed that did not pass RNA and cDNA library quality control testing. One sample was removed due to large deviation on PCA and poor sequence alignment. For phosphoproteomic data, two sample outliers in intensities and peptide detections were discarded prior to quantitative analysis: Fibrin 1 h (PRIDE sample ID FU20180420-23) and one iC3b 1 h (PRIDE sample ID FU20180420-05) samples. No samples or animals were excluded from any other analyses.
Replication	The number of experimental repeats is detailed at the bottom of each legend for each figure. All attempts at replication following the protocols described in the methods were successful.
Randomization	Mice were randomized and blindly coded for group assignment and data collection for IHC and ICC experiments. For in vivo stereotactic plasma injections, mice were randomized and blindly coded for group assignment and data collection. For all scRNA-seq experiments, mice were randomized by sex and genotype prior to sample preparation.
Blinding	Stereotactic surgery was performed blinded to the experimental groups. For IHC experiments, image acquisition and quantification was performed by observers blinded to experimental conditions. Images were quantified independently by two blinded observers.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

Purified mouse IgG2b isotype control (clone MPC-11, BioXcell). IHC: GP91phox (1:150 dilution; 53, BD Biosciences), rabbit anti-IBA1 (1:500; 019-19741, Wako), goat anti-APOE (1:50; AB947, MilliporeSigma), p-PXN (1:500, rabbit polyclonal, #PAB7932, Abnova), p-MEK2 (1:500, rabbit polyclonal, #28955-1-AP, Thermo Fisher Scientific), and Alexa 647, 488 and Cy3 (1:500 dilution; Jackson ImmunoResearch). Immunoblots: p-NCF2 (1:1000, rabbit polyclonal, #PA5-105094, Thermo Fisher Scientific), p-PXN (1:1000, rabbit polyclonal, #PAB7932, Abnova), paxillin (1:1000, rabbit monoclonal, #ab32115, Abcam), p-MEK2 (1:1000, rabbit polyclonal, #28955-1-AP, Thermo Fisher Scientific), MEK1/2 (1:10,000, rabbit monoclonal, #ab178876, Abcam), and GAPDH (1:10,000, rabbit monoclonal, #2118, Cell Signaling Technology). FACS: CD11b (M1/70; Biolegend) and CD45 (30-F11; Biolegend).

Validation

All antibodies used in this study are from commercial sources and have been validated by the vendors and previous studies done by our lab or other labs. IgG2b, CD11b, CD45, GP91phox, IBA1, GAPDH were previously validated in our publications Ryu et al., Nat Commun 6, (2015); Ryu et al., Nat Immunol., 19, 1212-1223 (2018); Mendiola et al. Nat Immunol., 21, 513-524 (2020). APOE, manufactures information on validation not available but was used in Margeta et al Immunity 55, 1627-1644.e7 (2022); p-MEK2, manufactures information on validation not available, p-PAK, manufactures information on validation not available; MEK1/2, manufactures information on validation not available but was used in Ben-Addi et al Proc Natl Acad Sci USA 111, E2394-403 (2014); p-NCF2, manufactures information on validation not available. Paxillin was validated in KO cell lines (Abcam).

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

RAW 264.7 mouse macrophage cell line was obtained from ATCC and cultured in DMEM supplemented with 10% FBS.

Authentication

RAW 264.7 macrophages were not authenticated

Mycoplasma contamination

The cell line was tested and was free from mycoplasma contamination.

Commonly misidentified lines
(See [ICLAC](#) register)

No commonly misidentified cell lines were used.

Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

Male and Female C57BL/6J and B6.Cg-Tg(APP^SWFLon,PSEN1^{*}M146L*L286V) 6799Vas/Mmjax (5XFAD) mice were purchased from the Jackson Laboratory. Fga^{-/-} and Fgg390-396A mice were obtained from Dr. Jay Degen (University of Cincinnati, OH, USA). 5XFAD mice were crossed with Fgg390-396A mice to generate 5XFAD:Fgg390-396A mice. Male and female mice were used in this study. Sprague-Dawley female rats with litters were purchased from Charles River. Animals were housed under IACUC guidelines in a temperature and humidity-controlled facility with 12 h light–12 h dark cycle and ad libitum feeding.

Wild animals

The study did not involve wild animals

Field-collected samples

The study did not involve samples collected from the field

Ethics oversight

All animal protocols were approved by the Committee of Animal Research at the University of California, San Francisco, and were in accordance with the National Institutes of Health guidelines.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Mice were perfused with ice-cold phosphate-buffered saline (PBS) and cortical and hippocampal brain regions were carefully dissected from each animal and incubated with 1 mg mL⁻¹ collagenase D (Sigma-Aldrich) and 0.05 mg mL⁻¹ DNase1 (Sigma-Aldrich) for 30 min at 37C. Myelin was depleted using the debris removal kit as described⁵⁶. Myelin-cleared cell suspensions were treated for 5 min at 4C with Fc-block in BSA staining buffer (BD Biosciences) and then incubated for 30 min at 4C with CD11b APC-Cy7 (M1/70) antibodies. For ROS and live cell labeling, cells were incubated with 10 uM 2',7'-dichlorofluorescein diacetate (DCFDA) at 4C for 30 min and then incubated with 1 uM Sytox blue live/dead stain for 5 min at 4C. Using a FACSAria II (BD Biosciences), cells were sorting into live Sytox blue-CD11b+ROS- and live Sytox blue-CD11b+ROS+ cell populations from 12m 5XFAD and WT mice. Sorted cells were kept on ice until all samples were collected and then resuspended in cold PBS supplemented with 2% FBS at 250 cells uL⁻¹ and immediately processed for scRNA-seq

Instrument

ARIAll (BD)

Software

BD FACSDiva v8 and FlowJo software v10

Cell population abundance

When cells were sorted or enriched, the purity was confirmed by flow cytometry and routinely >95 %.

Gating strategy

5XFAD Tox-seq: Single cells were gated by FSC-A/SSC-A and then doublet discrimination was performed first by FSC-H/FSC-W followed by SSC-H/SSC-W. Next, live sytox- CD11b+ cells were gated for, then cells were sorted based on ROS- and ROS+ (assessed by DCFDA).

Bulk RNA-seq experiment: Single cells were gated by FSC-A/SSC-A and then doublet discrimination was performed first by FSC-H/FSC-W followed by SSC-H/SSC-W. Then, microglia cells were gated by CD45loCD11b+ expression.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.